<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83874</article-id><article-id pub-id-type="doi">10.7554/eLife.83874</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>The Dantu blood group prevents parasite growth <italic>in vivo</italic>: Evidence from a controlled human malaria infection study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-193052"><name><surname>Kariuki</surname><given-names>Silvia N</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0801-5285</contrib-id><email>SNKariuki@kemri-wellcome.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-53566"><name><surname>Macharia</surname><given-names>Alexander W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-296516"><name><surname>Makale</surname><given-names>Johnstone</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296517"><name><surname>Nyamu</surname><given-names>Wilfred</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15909"><name><surname>Hoffman</surname><given-names>Stephen L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-219405"><name><surname>Kapulu</surname><given-names>Melissa C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-9838"><name><surname>Bejon</surname><given-names>Philip</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227384"><name><surname>Rayner</surname><given-names>Julian C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9835-1014</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-8373"><name><surname>Williams</surname><given-names>Thomas N</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4456-2382</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><on-behalf-of>On behalf of for the CHMI-SIKA Study Team</on-behalf-of><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04r1cxt79</institution-id><institution>Centre for Geographic Medicine Research (Coast), KEMRI-Wellcome Trust Research Programme</institution></institution-wrap><addr-line><named-content content-type="city">Kilifi</named-content></addr-line><country>Kenya</country></aff><aff id="aff2"><label>2</label><institution>Sanaria Incorporate</institution><addr-line><named-content content-type="city">Rockville</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013meh722</institution-id><institution>Cambridge Institute for Medical Research, University of Cambridge</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Institute for Global Health Innovation, Department of Surgery and Cancer, Imperial College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Wesolowski</surname><given-names>Amy</given-names></name><role>Reviewing Editor</role><aff><institution>Johns Hopkins Bloomberg School of Public Health</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>van der Meer</surname><given-names>Jos W</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05wg1m734</institution-id><institution>Radboud University Medical Centre</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>13</day><month>06</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83874</elocation-id><history><date date-type="received" iso-8601-date="2022-09-30"><day>30</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-05-11"><day>11</day><month>05</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-09-22"><day>22</day><month>09</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.09.21.22280031"/></event></pub-history><permissions><copyright-statement>© 2023, Kariuki et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Kariuki et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83874-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83874-figures-v1.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>The long co-evolution of <italic>Homo sapiens</italic> and <italic>Plasmodium falciparum</italic> has resulted in the selection of numerous human genetic variants that confer an advantage against severe malaria and death. One such variant is the Dantu blood group antigen, which is associated with 74% protection against severe and complicated <italic>P. falciparum</italic> malaria infections in homozygous individuals, similar to that provided by the sickle haemoglobin allele (HbS). Recent <italic>in vitro</italic> studies suggest that Dantu exerts this protection by increasing the surface tension of red blood cells, thereby impeding the ability of <italic>P. falciparum</italic> merozoites to invade them and reducing parasite multiplication. However, no studies have yet explored this hypothesis <italic>in vivo</italic>.</p></sec><sec id="abs2"><title>Methods:</title><p>We investigated the effect of Dantu on early phase <italic>P. falciparum</italic> (Pf) infections in a controlled human malaria infection (CHMI) study. 141 sickle-negative Kenyan adults were inoculated with 3.2 × 10<sup>3</sup> aseptic, purified, cryopreserved Pf sporozoites (PfSPZ Challenge) then monitored for blood-stage parasitaemia for 21 days by quantitative polymerase chain reaction (qPCR)analysis of the 18S ribosomal RNA <italic>P. falciparum</italic> gene. The primary endpoint was blood-stage <italic>P. falciparum</italic> parasitaemia of ≥500/μl while the secondary endpoint was the receipt of antimalarial treatment in the presence of parasitaemia of any density. On study completion, all participants were genotyped both for Dantu and for four other polymorphisms that are associated with protection against severe falciparum malaria: α<sup>+</sup>-thalassaemia, blood group O, G6PD deficiency, and the rs4951074 allele in the red cell calcium transporter <italic>ATP2B4</italic>.</p></sec><sec id="abs3"><title>Results:</title><p>The primary endpoint was reached in 25/111 (22.5%) non-Dantu subjects in comparison to 0/27 (0%) Dantu heterozygotes and 0/3 (0.0%) Dantu homozygotes (p=0.01). Similarly, 49/111 (44.1%) non-Dantu subjects reached the secondary endpoint in comparison to only 7/27 (25.9%) and 0/3 (0.0%) Dantu heterozygotes and homozygotes, respectively (p=0.021). No significant impacts on either outcome were seen for any of the other genetic variants under study.</p></sec><sec id="abs4"><title>Conclusions:</title><p>This study reveals, for the first time, that the Dantu blood group is associated with high-level protection against early, non-clinical, <italic>P. falciparum</italic> malaria infections <italic>in vivo</italic>. Learning more about the mechanisms involved could potentially lead to new approaches to the prevention or treatment of the disease. Our study illustrates the power of CHMI with PfSPZ Challenge for directly testing the protective impact of genotypes previously identified using other methods.</p></sec><sec id="abs5"><title>Funding:</title><p>The Kenya CHMI study was supported by an award from Wellcome (grant number 107499). SK was supported by a Training Fellowship (216444/Z/19/Z), TNW by a Senior Research Fellowship (202800/Z/16/Z), JCR by an Investigator Award (220266/Z/20/Z), and core support to the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya (203077), all from Wellcome. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</p></sec><sec id="abs6"><title>Clinical trial number:</title><p><related-object id="RO1" source-type="clinical-trials-registry" source-id="ClinicalTrials.gov" source-id-type="registry-name" document-id="NCT02739763" document-id-type="clinical-trial-number" xlink:href="https://clinicaltrials.gov/show/NCT02739763">NCT02739763</related-object></p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>malaria</kwd><kwd>challenge study</kwd><kwd>host genetics</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd><italic>P. falciparum</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>107499</award-id><principal-award-recipient><name><surname>Kapulu</surname><given-names>Melissa C</given-names></name><name><surname>Bejon</surname><given-names>Philip</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>216444/Z/19/Z</award-id><principal-award-recipient><name><surname>Kariuki</surname><given-names>Silvia N</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>202800/Z/16/Z</award-id><principal-award-recipient><name><surname>Williams</surname><given-names>Thomas N</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>220266/Z/20/Z</award-id><principal-award-recipient><name><surname>Rayner</surname><given-names>Julian C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Strongly protective effect conferred by the Dantu blood group variant against early, non-clinical, <italic>Plasmodium falciparum</italic> malaria infections <italic>in vivo</italic>.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p><italic>Plasmodium falciparum</italic> malaria has been the pre-eminent cause of child morbidity and mortality in the tropics and sub-tropics for much of the last 5000 y. As a consequence, it has had a substantial impact on the human genome through the positive selection of multiple polymorphisms that confer a survival advantage against the disease (<xref ref-type="bibr" rid="bib36">Williams, 2017</xref>). The best studied affect the biology of red blood cells (RBCs), which host malaria parasites for most of their life cycle in humans, the rs334 A&gt;T β<sup>s</sup> sickle mutation in <italic>HBB</italic> (<xref ref-type="bibr" rid="bib35">Williams, 2016</xref>), α-thalassaemia (<xref ref-type="bibr" rid="bib34">Williams et al., 2005</xref>), and blood group O (<xref ref-type="bibr" rid="bib6">Fry et al., 2008</xref>) all being important examples.</p><p>Recently, we identified a new variant which is associated with high-level protection against severe <italic>P. falciparum</italic> malaria to a degree that is close to that of sickle cell trait (HbAS), the strongest malaria-protective condition yet described (<xref ref-type="bibr" rid="bib18">Malaria Genomic Epidemiology Network, 2014</xref>). The rare Dantu blood group antigen, which results from a genetic rearrangement within the glycophorin (<italic>GYP</italic>) cluster, was shown to confer 74% protection against severe malaria in homozygous individuals (<xref ref-type="bibr" rid="bib2">Band et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Ndila et al., 2018</xref>). Subsequent <italic>in vitro</italic> studies have suggested that this protection is explained by the resistance of Dantu RBCs to invasion by <italic>P. falciparum</italic> merozoites (<xref ref-type="bibr" rid="bib14">Kariuki et al., 2020</xref>), thereby preventing infections from progressing to become severe or ultimately fatal. However, this hypothesis has not been tested directly <italic>in vivo</italic> to date.</p><p>In this study, we have investigated the impact of the Dantu blood group on <italic>in vivo P. falciparum</italic> parasite growth and clinical disease progression through a controlled human malaria infection (CHMI) study with aseptic, purified, cryopreserved <italic>P. falciparum</italic> sporozoites (PfSPZ Challenge) conducted in semi-immune Kenyan adults. To the best of our knowledge, this is the first time that CHMI has been used to directly explore the impact of Dantu on parasite growth <italic>in vivo</italic>.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study design and population</title><p>The primary aim of the Kenya CHMI study was to investigate the impacts of naturally acquired immunity on early-phase malaria infections (<xref ref-type="bibr" rid="bib10">Kapulu et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Kapulu et al., 2021</xref>). Briefly, 161 healthy adult volunteers living in areas of varying malaria transmission were inoculated by direct venous inoculation (DVI) with 3.2 × 10<sup>3</sup> <italic>P. falciparum</italic> sporozoites (PfSPZ) of Sanaria PfSPZ Challenge (NF54) (<xref ref-type="bibr" rid="bib25">Roestenberg et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">Mordmüller et al., 2015</xref>). With a sample size of 161 individuals, we had 80% power to detect a single variable with an effect size (r<sup>2</sup>) of 0.3 that accounts for 15% of the variability in parasite growth, as previously described (<xref ref-type="bibr" rid="bib10">Kapulu et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Kapulu et al., 2021</xref>). Because of its major impacts on both malaria susceptibility (<xref ref-type="bibr" rid="bib1">Allison, 1954</xref>) and disease progression (<xref ref-type="bibr" rid="bib31">Taylor et al., 2012</xref>), and in view of results from a previous CHMI with PfSPZ Challenge conducted in Gabon (<xref ref-type="bibr" rid="bib17">Lell et al., 2018</xref>), recruitment was restricted to those who were negative for both sickle cell trait and disease. After inoculation, venous blood samples were collected twice daily from days 7–14, and then once every day from day 15 until the end of the experiment on day 21, and screened for parasitaemia by quantitative polymerase chain reaction (qPCR) analysis of the <italic>P. falciparum</italic> 18S ribosomal RNA gene. For each participant, the endpoint was considered met, and anti-malarial treatment administered, when a threshold of 500 <italic>P</italic>. <italic>falciparum</italic> parasites/µl was reached. Participants were treated earlier if signs and symptoms were observed in association with blood film positivity at any parasite density, and on day 21 post-inoculation regardless of outcome. While qPCR was used as the primary measurement of parasitaemia because it is much more sensitive than microscopy at low density (<xref ref-type="bibr" rid="bib3">Bejon et al., 2006</xref>), thick film blood smears were also performed as an additional precaution, and participants were treated if they became blood film positive at any density, an approach that accords with that used in other CHMI studies (<xref ref-type="bibr" rid="bib29">Sheehy et al., 2012</xref>; <xref ref-type="bibr" rid="bib20">Murphy et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Hodgson et al., 2014</xref>; <xref ref-type="bibr" rid="bib9">Kamau et al., 2014</xref>; <xref ref-type="bibr" rid="bib8">Hodgson et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Seilie et al., 2019</xref>; <xref ref-type="bibr" rid="bib27">Salkeld et al., 2022</xref>). Participants were recruited during 2016, 2017, and 2018 into three successive cohorts from three different malaria transmission zones: Kilifi North (no- to low-transmission) and Kilifi South (moderate transmission), both on the coast, and Ahero (moderate to high transmission) in Western Kenya. We tested for antimalarial drugs as described in a previous publication (<xref ref-type="bibr" rid="bib11">Kapulu et al., 2021</xref>). Briefly, antimalarial drugs were measured retrospectively in all volunteers using samples collected on both the day before the challenge and 8 days after challenge. Plasma samples were tested by liquid chromatography-tandem mass spectrometry in two independent laboratories. Sulfadoxine, pyrimethamine, and chloroquine levels were measured at the Strathmore University in Nairobi, Kenya, while artemether and dihydroartemisinin concentrations were measured at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok, Thailand. The study was conducted at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, and was registered on ClinicalTrials.gov (NCT02739763).</p></sec><sec id="s2-2"><title>Genotyping for Dantu and other malaria-protective variants</title><p>Whole blood samples were collected at the point of recruitment into tubes containing EDTA and stored at –80°C pending batch processing at the end of the study. Genomic DNA was extracted following the manufacturer’s instructions using a QIAmp 96 DNA QIAcube HT kit on a QIAcube HT System (QIAGEN, Manchester, UK). Genotyping for Dantu was performed using ABI TaqMan SNP genotyping Assays-by-Design primers and probes on an ABI 7900HT PCR machine, as previously described (<xref ref-type="bibr" rid="bib13">Kariuki et al., 2009</xref>). Dantu genotypes were inferred from the rs186873296 <italic>FREM3</italic> allele, which is in strong linkage disequilibrium with the Dantu structural rearrangement (<xref ref-type="bibr" rid="bib2">Band et al., 2015</xref>). The following primer sequence was used for the rs186873296 SNP: <named-content content-type="sequence">ATGTGAAGAAGCTGGGAACCCTGTC</named-content>[A/G]<named-content content-type="sequence">TACAAGAAATGACAAAGAAAGCTT</named-content>, with A being the reference allele. For comparative purposes, we also genotyped participants for a range of other polymorphisms that have been reproducibly associated with protection from severe and complicated malaria in other studies. We typed for the common African form of G6PD deficiency, caused by the <italic>G6PD</italic> c.202T mutation (<xref ref-type="bibr" rid="bib5">Clarke et al., 2017</xref>), the blood group O mutation in <italic>ABO</italic> (<xref ref-type="bibr" rid="bib26">Rowe et al., 2007</xref>) and the rs4951074 allele in <italic>ATP2B4</italic> (<xref ref-type="bibr" rid="bib18">Malaria Genomic Epidemiology Network, 2014</xref>) using TaqMan SNP genotyping assays, and for the -α<sup>3.7I</sup> deletional form of α<sup>+</sup>-thalassaemia by gap PCR (<xref ref-type="bibr" rid="bib32">Wambua et al., 2006</xref>). To aid ease of comparison across all variants tested, the genotype groups are categorised as ‘Homozygous reference’ for individuals with two copies of the reference allele, ‘Heterozygous’ for individuals with one copy of the reference allele and one copy of the derived allele, and ‘Homozygous derived’ for individuals with two copies of the derived allele.</p></sec><sec id="s2-3"><title>Statistical analysis</title><p>We considered three distinct outcomes, each capturing a different aspect of the parasitological and clinical progress of malaria infections: (a) whether infections progressed to reach the pre-defined treatment threshold of 500 parasites/µl; (b) whether or not participants received malaria treatment for either clinical or parasitological reasons; (c) the time from inoculation to treatment in participants who did receive treatment. We made (a) the primary endpoint for this analysis because the hypothesis we were testing concerned <italic>in vivo</italic> parasite growth rather than susceptibility to symptoms. We conducted between-genotype comparisons both by univariate analysis and by multivariate analysis with adjustment for other malaria-protective genes, anti-schizont antibody concentration, and location of residence, of which the latter two were significantly associated with the same outcomes in an earlier analysis of the same cohort (<xref ref-type="bibr" rid="bib12">Kapulu et al., 2022</xref>). We used the Fisher’s exact test using the fmsb package (version 0.7.3) in R to test for any differences in the proportions of individuals that reached the pre-defined treatment threshold of 500 parasites/μl and to test for any differences in the proportions of individuals that required treatment across genotype groups. We also compared the treatment outcomes for the heterozygous- and homozygous-derived genotypes, individually, to the homozygous reference genotype by pairwise analysis.</p><p>To test for associations between each variant genotype and the treated or untreated categorical outcome, we used multivariate logistic regression using the glm function in the stats package (version 3.6.2) in R using additive models for each variant, where each variant genotype was coded as zero, one, or two copies of the derived allele. Each multivariable model adjusted for other malaria-protective variants, anti-schizont antibody concentration, and location of residence.</p><p>We used the Kruskal–Wallis test (stats package version 3.6.2) and the Dunn’s test (FSA package version 0.9.3) to investigate between-group differences in maximum parasitaemia. Finally, we compared time to treatment using Kaplan–Meier survival curves with univariate comparisons across genotype groups performed using the Log-Rank test, and Cox regression models for multivariate analyses, using the survival package (version 3.2.13) in R. All statistical analyses were performed using R V3.6.2 (<xref ref-type="bibr" rid="bib24">R Development Core Team, 2017</xref>).</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><p>Of 161 volunteers recruited to the study, 19 were excluded, either because non-CHMI parasite strains were detected in post-CHMI samples (suggesting the presence of coincidental natural infections) (n = 7), or because antimalarial drugs were detected in pre-CHMI samples (n = 12) (<xref ref-type="fig" rid="fig1">Figure 1</xref>) (<xref ref-type="bibr" rid="bib11">Kapulu et al., 2021</xref>). After these exclusions, data from 142 individuals contributed to the current analysis. Genotyping revealed that 30 of these individuals were either heterozygous or homozygous for the Dantu allele. We did not get Dantu genotype data on one individual due to poor quality of the DNA sample; therefore, Dantu genotype data on 141 out of the 142 participants was used in the downstream analysis (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Study design and participant recruitment.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83874-fig1-v1.tif"/></fig><sec id="s3-1"><title>The Dantu variant protects against <italic>P. falciparum</italic> growth <italic>in vivo</italic></title><p>While infections progressed to the point of reaching the pre-determined treatment threshold of 500 parasites/µl in 25/142 (17.6%) of all volunteers, the proportions varied markedly by Dantu genotype. None of the thirty (0.0%) Dantu carriers reached this threshold in comparison to 25/111 (22.5%) of the non-Dantu individuals (p=0.01) (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). The difference in the proportion of Dantu heterozygous (0/27; 0%) and non-Dantu individuals reaching the treatment threshold was strongly significant (p=0.004) but did not reach statistical significance in the case of Dantu homozygotes 0/3 (0.0%) because of the small number of individuals in this group.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The impact of human genotype on parasite growth.</title><p>Following inoculation of volunteers with Pf sporozoites, parasitaemia was monitored by quantitative PCR (y-axis) over the full duration of the study (x-axis). The different panels indicate the specific variants that were studied. The red dots indicate only the individuals that exhibited febrile symptoms and met treatment criteria. The different genotype groups for all the variants are categorised as ‘Homozygous reference’ for individuals with two copies of the reference allele (red lines), ‘Heterozygous’ for individuals with one copy of the reference allele and one copy of the derived allele (green lines), and ‘Homozygous derived’ for individuals with two copies of the derived allele (blue lines). αα/αα, no α-thalassaemia; −α/αα, heterozygous α-thalassaemia; −α/−α, homozygous α-thalassaemia. * For G6PD, male and female were combined as C/CC = normal (wild type hemizygous males and homozygous females), CT = carrier females, and T/TT = G6PD-deficient hemizygous males and homozygous females. All volunteers were typed for all variants, and any one individual may carry a mixture of genotypes – the potential confounding effect of this was controlled for in multivariate analysis. The tables adjacent to each plot show the results from Fisher’s exact tests investigating differences in the proportion of participants that reached the pre-defined treatment threshold of 500 parasites/μl (n) compared to the total number within each genotype category (N).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="text" mime-subtype="plain" xlink:href="elife-83874-fig2-data1-v1.txt"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Related to <xref ref-type="fig" rid="fig2">Figure 2</xref> table.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83874-fig2-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83874-fig2-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>The proportion of participants reaching the pre-defined treatment parasitaemia threshold of 500 parasites/μl by genotype category.</title><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>Related to <xref ref-type="table" rid="table1">Table 1</xref>.</title></caption><media mimetype="text" mime-subtype="plain" xlink:href="elife-83874-table1-data1-v1.txt"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variant</th><th align="left" valign="bottom">Genotype</th><th align="left" valign="bottom">n/N</th><th align="left" valign="bottom">%</th><th align="left" valign="bottom">p value overall</th><th align="left" valign="bottom">p value homozygous reference vs. heterozygous</th><th align="left" valign="bottom">p value homozygous reference vs. homozygous derived</th></tr></thead><tbody><tr><td align="left" valign="bottom">Dantu rs186873296</td><td align="left" valign="bottom">Non-Dantu (AA)</td><td align="char" char="." valign="bottom">25/111</td><td align="char" char="." valign="bottom">22.5</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom">0.004</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Heterozygous (AG)</td><td align="char" char="." valign="bottom">0/27</td><td align="char" char="." valign="bottom">0.0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Dantu homozygous (GG)</td><td align="char" char="." valign="bottom">0/3</td><td align="char" char="." valign="bottom">0.0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>G6PD</italic> +202 rs1050828</td><td align="left" valign="bottom">Homozygous reference (C/CC)</td><td align="char" char="." valign="bottom">20/110</td><td align="char" char="." valign="bottom">18.2</td><td align="char" char="." valign="bottom">0.505</td><td align="char" char="." valign="bottom">0.739</td><td align="char" char="." valign="bottom">0.463</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Heterozygous (CT)</td><td align="char" char="." valign="bottom">4/17</td><td align="char" char="." valign="bottom">23.5</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Homozygous derived (T/TT)</td><td align="char" char="." valign="bottom">1/15</td><td align="char" char="." valign="bottom">6.7</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>ABO</italic> rs8176719</td><td align="left" valign="bottom">Non-O</td><td align="char" char="." valign="bottom">13/64</td><td align="char" char="." valign="bottom">20.3</td><td align="char" char="." valign="bottom">0.517</td><td align="char" char="." valign="bottom">0.517</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">O</td><td align="char" char="." valign="bottom">12/75</td><td align="char" char="." valign="bottom">16.0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">α-thalassaemia</td><td align="left" valign="bottom">Homozygous reference (αα/αα)</td><td align="char" char="." valign="bottom">6/48</td><td align="char" char="." valign="bottom">12.5</td><td align="char" char="." valign="bottom">0.408</td><td align="char" char="." valign="bottom">0.328</td><td align="char" char="." valign="bottom">0.29</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Heterozygous (−α/αα)</td><td align="char" char="." valign="bottom">14/70</td><td align="char" char="." valign="bottom">20.0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Homozygous derived (−α/−α)</td><td align="char" char="." valign="bottom">5/21</td><td align="char" char="." valign="bottom">23.8</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>ATP2B4</italic> rs4951074</td><td align="left" valign="bottom">Homozygous reference (GG)</td><td align="char" char="." valign="bottom">11/62</td><td align="char" char="." valign="bottom">17.7</td><td align="char" char="." valign="bottom">0.876</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">0.749</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Heterozygous (AG)</td><td align="char" char="." valign="bottom">11/57</td><td align="char" char="." valign="bottom">19.3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Homozygous derived (AA)</td><td align="char" char="." valign="bottom">3/23</td><td align="char" char="." valign="bottom">13.0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table><table-wrap-foot><fn><p>n = the number of participants that reached the pre-defined treatment threshold of 500 parasites/μl and were treated; N = the total number within each genotype category; αα/αα, no α-thalassaemia; −α/αα, heterozygous α-thalassaemia; −α/−α, homozygous α-thalassaemia. * For G6PD, male and female were combined as C/CC = normal (wild type hemizygous males and homozygous females), CT = carrier females, and T/TT = G6PD -deficient hemizygous males and homozygous females. We used the Fisher’s exact test to investigate differences in the proportions of individuals that reached the pre-defined treatment threshold of 500 parasites/μl, both for global comparisons across genotype groups, and for separate comparisons between genotype pairs, where the proportion of individuals that reached the treatment threshold of 500 parasites/μl in the heterozygous- and homozygous -derived genotypes were compared to the homozygous reference genotype.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Fewer Dantu carriers required malaria treatment</title><p>Although a threshold of 500 parasites/μl was considered the primary endpoint of the study and triggered the administration of antimalarial treatment per-protocol, some participants developed symptoms and were therefore treated before reaching this parasitaemia threshold. Only one quarter (7/27; 25.9%) of the Dantu heterozygotes and none (0/3; 0.0%) of the Dantu homozygotes (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="table" rid="table2">Table 2</xref>) received antimalarial treatment in comparison to 49/111 (44.1%) of the non-Dantu individuals. While this did not reach statistical significance on univariate analysis, we carried out multivariate regression analysis with the treated or untreated status as the dependent variable, and the Dantu variant as well as other genetic variants (as described below), anti-schizont antibody and location of residence as the independent variables. This analysis revealed that Dantu-carrying subjects overall were administered antimalarial treatment 83% less frequently (OR 0.17; 95% CI 0.04–0.55; p=0.007) than non-Dantu individuals (<xref ref-type="table" rid="table3">Table 3</xref>). In order to address the core issue of whether prior immunity was a confounder in our analysis, we used measurements of antibodies to whole schizont extract as a proxy indicator of transmission setting or ‘malaria exposure’ in our multivariate analyses. We compared anti-schizont antibody levels across Dantu genotype groups and found no differences (p=0.659) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The impact of each gene variant on the requirement for malaria treatment.</title><p>The proportion of individuals in each genotype category that required treatment over the course of the controlled human malaria infection (CHMI) study is shown on the y-axis. The number of treated individuals out of the total number in each genotype group is given in parenthesis above the bar graphs, while the p values from the Fisher’s exact tests comparing the differences in proportions of individuals that required treatment across genotype groups are also given above the bar graphs.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="text" mime-subtype="plain" xlink:href="elife-83874-fig3-data1-v1.txt"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83874-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>No differences in anti-schizont antibody levels were found across Dantu genotype groups.</title><p>The log-transformed anti-schizont antibody data were compared across Dantu genotype groups using a multivariate model with adjustments for other variant genotypes and location of residence.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="text" mime-subtype="plain" xlink:href="elife-83874-fig3-figsupp1-data1-v1.txt"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83874-fig3-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>The numbers and frequencies of individuals who received treatment before day 21 by genotypic category.</title><p><supplementary-material id="table2sdata1"><label>Table 2—source data 1.</label><caption><title>Related to <xref ref-type="table" rid="table2">Table 2</xref>.</title></caption><media mimetype="text" mime-subtype="plain" xlink:href="elife-83874-table2-data1-v1.txt"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variant</th><th align="left" valign="bottom">Genotype</th><th align="left" valign="bottom">n/N</th><th align="left" valign="bottom">%</th><th align="left" valign="bottom">Overall p value</th><th align="left" valign="bottom">Homozygous reference vs. heterozygous</th><th align="left" valign="bottom">Homozygous reference vs. homozygous derived</th></tr></thead><tbody><tr><td align="left" valign="bottom">Dantu rs186873296</td><td align="left" valign="bottom">Non-Dantu (AA)</td><td align="left" valign="bottom">49/111</td><td align="char" char="." valign="bottom">44.1</td><td align="char" char="." valign="bottom">0.10</td><td align="char" char="." valign="bottom">0.13</td><td align="char" char="." valign="bottom">0.26</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Heterozygous (AG)</td><td align="left" valign="bottom">7/27</td><td align="char" char="." valign="bottom">25.9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Dantu homozygous (GG)</td><td align="left" valign="bottom">0/3</td><td align="char" char="." valign="bottom">0.0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>G6PD</italic> +202 rs1050828*</td><td align="left" valign="bottom">Homozygous reference (C/CC)</td><td align="left" valign="bottom">46/110</td><td align="char" char="." valign="bottom">41.8</td><td align="char" char="." valign="bottom">0.28</td><td align="char" char="." valign="bottom">1.00</td><td align="char" char="." valign="bottom">0.16</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Heterozygous (CT)</td><td align="left" valign="bottom">7/17</td><td align="char" char="." valign="bottom">41.2</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Homozygous derived (T/TT)</td><td align="left" valign="bottom">3/15</td><td align="char" char="." valign="bottom">20.0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>ABO</italic> rs8176719</td><td align="left" valign="bottom">Non-O</td><td align="left" valign="bottom">28/64</td><td align="char" char="." valign="bottom">43.8</td><td align="char" char="." valign="bottom">0.39</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">0.39</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">O</td><td align="left" valign="bottom">27/75</td><td align="char" char="." valign="bottom">36.0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">α-thalassaemia</td><td align="left" valign="bottom">Homozygous reference (αα/αα)</td><td align="left" valign="bottom">19/48</td><td align="char" char="." valign="bottom">39.6</td><td align="char" char="." valign="bottom">0.79</td><td align="char" char="." valign="bottom">0.85</td><td align="char" char="." valign="bottom">0.79</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Heterozygous (−α/αα)</td><td align="left" valign="bottom">30/70</td><td align="char" char="." valign="bottom">42.9</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Homozygous derived (−α/−α)</td><td align="left" valign="bottom">7/21</td><td align="char" char="." valign="bottom">33.3</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>ATP2B4</italic> rs4951074</td><td align="left" valign="bottom">Homozygous reference (GG)</td><td align="left" valign="bottom">26/62</td><td align="char" char="." valign="bottom">41.9</td><td align="char" char="." valign="bottom">0.61</td><td align="char" char="." valign="bottom">1.00</td><td align="char" char="." valign="bottom">0.45</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Heterozygous (AG)</td><td align="left" valign="bottom">23/57</td><td align="char" char="." valign="bottom">40.4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Homozygous derived (AA)</td><td align="left" valign="bottom">7/23</td><td align="char" char="." valign="bottom">30.4</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>The association between each gene variant and the requirement for treatment after challenge.</title><p><supplementary-material id="table3sdata1"><label>Table 3—source data 1.</label><caption><title>Related to <xref ref-type="table" rid="table3">Table 3</xref>.</title></caption><media mimetype="text" mime-subtype="plain" xlink:href="elife-83874-table3-data1-v1.txt"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="3">Overall comparison across genotype groups</th><th align="left" valign="bottom" colspan="3">Homozygous reference vs. heterozygous</th><th align="left" valign="bottom" colspan="3">Homozygous reference vs. homozygous derived</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Variant</bold></td><td align="left" valign="bottom"><bold>Odds ratios</bold></td><td align="char" char="." valign="bottom"><bold>95%</bold> CI</td><td align="left" valign="bottom"><bold>p-value</bold></td><td align="left" valign="bottom"><bold>Odds ratios</bold></td><td align="char" char="." valign="bottom"><bold>95%</bold> CI</td><td align="left" valign="bottom"><bold>p value</bold></td><td align="left" valign="bottom"><bold>Odds ratios</bold></td><td align="char" char="." valign="bottom"><bold>95%</bold> CI</td><td align="left" valign="bottom"><bold>p value</bold></td></tr><tr><td align="left" valign="bottom">Dantu rs186873296</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="ndash" valign="bottom">0.04–0.55</td><td align="char" char="." valign="bottom">0.007</td><td align="char" char="." valign="bottom">0.20</td><td align="char" char="ndash" valign="bottom">0.04–0.83</td><td align="char" char="." valign="bottom">0.039</td><td align="char" char="." valign="bottom">0</td><td align="left" valign="bottom">NA – Inf</td><td align="char" char="." valign="bottom">0.990</td></tr><tr><td align="left" valign="bottom"><italic>G6PD</italic> +202 rs1050828</td><td align="char" char="." valign="bottom">0.60</td><td align="char" char="ndash" valign="bottom">0.28–1.19</td><td align="char" char="." valign="bottom">0.157</td><td align="char" char="." valign="bottom">1.71</td><td align="char" char="ndash" valign="bottom">0.41–6.59</td><td align="char" char="." valign="bottom">0.442</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="ndash" valign="bottom">0.02–0.97</td><td align="char" char="." valign="bottom">0.074</td></tr><tr><td align="left" valign="bottom"><italic>ABO</italic> rs8176719</td><td align="char" char="." valign="bottom">0.40</td><td align="char" char="ndash" valign="bottom">0.15–1.03</td><td align="char" char="." valign="bottom">0.064</td><td align="char" char="." valign="bottom">0.54</td><td align="char" char="ndash" valign="bottom">0.18–1.56</td><td align="char" char="." valign="bottom">0.259</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">α-thalassaemia</td><td align="char" char="." valign="bottom">0.91</td><td align="char" char="ndash" valign="bottom">0.46–1.73</td><td align="char" char="." valign="bottom">0.766</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="ndash" valign="bottom">0.31–3.04</td><td align="char" char="." valign="bottom">0.957</td><td align="char" char="." valign="bottom">0.87</td><td align="char" char="ndash" valign="bottom">0.18–3.22</td><td align="char" char="." valign="bottom">0.758</td></tr><tr><td align="left" valign="bottom"><italic>ATP2B4</italic> rs4951074</td><td align="char" char="." valign="bottom">0.84</td><td align="char" char="ndash" valign="bottom">0.43–1.63</td><td align="char" char="." valign="bottom">0.619</td><td align="char" char="." valign="bottom">0.53</td><td align="char" char="ndash" valign="bottom">0.17–1.58</td><td align="char" char="." valign="bottom">0.266</td><td align="char" char="." valign="bottom">0.57</td><td align="char" char="ndash" valign="bottom">0.10–2.58</td><td align="char" char="." valign="bottom">0.491</td></tr></tbody></table></table-wrap></sec><sec id="s3-3"><title>Peak parasitaemias were lower in Dantu-carrying participants</title><p>The proportion of participants who became PCR-positive at any parasitaemia was similar at 86/111 (77.5%) in the non-Dantu and 20/27 (74.1%) and 2/3 (66.7%) among Dantu heterozygotes and homozygotes, respectively (p=0.745) (<xref ref-type="fig" rid="fig4">Figure 4</xref>). However, maximum parasitaemias were considerably higher in non-Dantu than in Dantu-carrying individuals. Peak parasitaemias reached 9694 parasites/μl in the non-Dantu group in comparison with 411 parasites/μl in the Dantu heterozygotes and only 3 parasites/μl among the Dantu homozygotes (non-Dantu vs. Dantu heterozygotes p=0.028; non-Dantu vs. Dantu homozygotes p=0.141; and non-Dantu vs. Dantu heterozygotes and homozygotes combined p=0.009) (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Similarly, the median parasitaemia among those who did become PCR-positive was 112 parasites/μl in the non-Dantu, 13 parasites/μl in the Dantu heterozygous, and 2 parasites/μl in the Dantu homozygous groups, respectively, although these differences did not reach statistical significance (non-Dantu vs. Dantu heterozygotes p=0.108; non-Dantu vs. Dantu homozygotes p=0.256; and non-Dantu vs. combined Dantu heterozygotes and homozygotes p=0.068) (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Peak parasitaemias were lower in Dantu variant carriers.</title><p>Maximum parasitaemia values for individuals across Dantu genotype groups, with dashed line indicating the treatment threshold of 500 parasites/μl. The table below the figure shows the numbers and frequencies of individuals in each genotype category that were PCR-positive over the course of the controlled human malaria infection (CHMI) study. n = the number of participants that were PCR-positive; N = the total number within the genotype category. Statistical comparisons of proportions of PCR-positive individuals across genotype groups and pairwise comparisons between genotype groups were performed using the Fisher’s exact test. Statistical comparisons of maximum and median parasitaemia between genotype groups were performed using the Kruskal–Wallis test, and post-hoc Dunn’s test for pairwise differences between the genotype groups.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="text" mime-subtype="plain" xlink:href="elife-83874-fig4-data1-v1.txt"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Related to <xref ref-type="fig" rid="fig4">Figure 4</xref> table.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83874-fig4-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83874-fig4-v1.tif"/></fig></sec><sec id="s3-4"><title>Time to treatment was significantly longer in Dantu-carrying than non-Dantu individuals</title><p>Among the participants who did receive treatment, the time to treatment was significantly longer among Dantu-carrying than non-Dantu individuals. While the univariate comparisons across genotype groups, performed using the Log-Rank test in the Kaplan–Meier survival curves, did not reach statistical significance (<xref ref-type="fig" rid="fig5">Figure 5a</xref>), the multivariate Cox regression analysis with adjustments for other malaria-protective variants, anti-schizont antibody concentration, and location of residence showed that time to treatment was significantly longer among Dantu-carrying than non-Dantu individuals, the overall hazard ratio being 0.39 (CI 0.17–0.87; p=0.022) (<xref ref-type="fig" rid="fig5">Figure 5b</xref>). A dose-dependent effect of the Dantu genotype was also seen as none of the three Dantu homozygotes required treatment and the time to treatment was significantly longer in Dantu heterozygous than in non-Dantu individuals (HR = 0.41, p=0.042) (<xref ref-type="fig" rid="fig5">Figure 5b</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Time to treatment was longer in Dantu variant carriers.</title><p>The impact of each gene variant on time to treatment was analysed by (<bold>a</bold>) Kaplan–Meier survival curves, with univariate comparisons across genotype groups performed using the Log-Rank test and (<bold>b</bold>) multivariate Cox regression models, with each variant genotype coded as zero, one, or two copies of the homozygous derived allele in an additive model, adjusting for the other four malaria-protective variants, anti-schizont antibody concentration, and location of residence. Pairwise analysis compared the time to treatment in the heterozygous- and homozygous-derived genotypes to the homozygous reference genotype.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Related to <xref ref-type="fig" rid="fig5">Figure 5a</xref>.</title></caption><media mimetype="text" mime-subtype="plain" xlink:href="elife-83874-fig5-data1-v1.txt"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Related to <xref ref-type="fig" rid="fig5">Figure 5b</xref>.</title></caption><media mimetype="text" mime-subtype="plain" xlink:href="elife-83874-fig5-data2-v1.txt"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Related to <xref ref-type="fig" rid="fig5">Figure 5b</xref> table.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83874-fig5-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83874-fig5-v1.tif"/></fig></sec><sec id="s3-5"><title>No significant impacts were seen with regard to any of the outcomes under study for any of the remaining RBC polymorphisms</title><p>While our primary analysis focused on the Dantu genotype, individuals in malaria-endemic regions often carry more than one malaria protection-associated genotype (<xref ref-type="bibr" rid="bib22">Ndila et al., 2018</xref>). We therefore typed individuals for α-thalassaemia, blood group O, G6PD deficiency and <italic>ATP2B4</italic> alleles, and carried out the same set of analysis as above for each genotype. Each of these genotypic groups also included, by random chance, individuals of different genotypes for the other variants of interest. As the genotyping was conducted at the end of the study, and the study included only a relatively small number of individuals overall, it was not possible to limit each group to those who were reference homozygotes for all the other variants of interest. Instead, we used multivariate analyses to check that any differences seen on univariate analysis were not explained by the presence of other variants or confounders. No significant differences were seen in any of the study outcomes between the different genotype groups (<xref ref-type="fig" rid="fig2">Figures 2</xref>, <xref ref-type="fig" rid="fig3">3</xref> and <xref ref-type="fig" rid="fig5">5</xref>, <xref ref-type="table" rid="table1 table2 table3">Tables 1–3</xref>). As noted above, the impact of Dantu on malaria treatment was independent of the presence or absence of these other genetic variants in multivariate analysis.</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Through the analysis of data from a CHMI study with PfSPZ Challenge injection conducted in Kenyan adults, we have shown that the Dantu blood group is associated with prevention of parasite growth <italic>in vivo</italic>. While more than 20% of Dantu-negative volunteers developed bloodstream malaria infections that reached a pre-defined threshold of 500 parasites/μl following controlled PfSPZ administration, this threshold was not reached by any of the 30 Dantu-positive volunteers. This is the first time that Dantu has been shown to protect against early-stage malaria infections. Our study suggests that Dantu protects against severe and complicated malaria (<xref ref-type="bibr" rid="bib22">Ndila et al., 2018</xref>; <xref ref-type="bibr" rid="bib2">Band et al., 2015</xref>) by preventing the disease from becoming established in its earliest phase. This is consistent with recent <italic>in vitro</italic> observations that have demonstrated a link between Dantu genotype and susceptibility to red blood cell invasion by <italic>P. falciparum</italic> merozoites, which we previously predicted would lead to reduced parasite growth <italic>in vivo</italic> (<xref ref-type="bibr" rid="bib14">Kariuki et al., 2020</xref>). That mechanistic study revealed that the Dantu genotype protects red blood cells from invasion by increasing their surface tension, which reduces the ability of merozoites to deform their surface and hence productively invade. Critically, this tension difference was greater in Dantu homozygotes than heterozygotes, as was the reduction in invasion efficiency, supporting a dose-dependent protective effect. This dose-dependency was similarly reflected in our current <italic>in vivo</italic> study, as while 44.1% of the Dantu-negative volunteers developed symptoms that precipitated malaria treatment, this occurred in only 25.9% of Dantu heterozygous and in none of the three (0%) Dantu homozygous volunteers. Similarly, the maximum parasitaemia observed was considerably higher in the non-Dantu than in the Dantu heterozygous and homozygous participants.</p><p>In contrast to CHMI studies in malaria-naïve populations, where most participants typically develop clinical malaria (<xref ref-type="bibr" rid="bib4">Church et al., 1997</xref>), less than one-fifth of the participants in this study reached a threshold of &gt;500 parasites/μl. This is probably because most of the participants in our study were residents of malaria-endemic communities and will therefore have been partially immune to the disease. Indeed, in previous analyses of data from the same study we have shown that infection outcome was attributable to the degree of prior exposure as estimated by the titre of anti-schizont antibodies (<xref ref-type="bibr" rid="bib12">Kapulu et al., 2022</xref>), as well as other measures of exposure including the antibody-dependent phagocytosis of both ring-infected and uninfected erythrocytes from parasite cultures (<xref ref-type="bibr" rid="bib21">Musasia et al., 2022</xref>) and the breadth of antibodies to <italic>P. falciparum</italic> Variant Surface Antigens (<xref ref-type="bibr" rid="bib15">Kimingi et al., 2022</xref>). As such, Dantu genotype was therefore clearly not the only factor at play in determining the clinical outcome in this study. However, our multivariate analysis adjusted for these factors (<xref ref-type="bibr" rid="bib12">Kapulu et al., 2022</xref>) as well as other malaria-protective genetic variants, and the significant association in that analysis underscores the strong protective effect conferred by Dantu. There were also no differences observed in anti-schizont antibody levels across Dantu genotype groups, suggesting that differences in pre-existing anti-malaria immunity between Dantu and non-Dantu cannot explain the differences seen in this study.</p><p>The protective impact of Dantu against <italic>in vivo</italic> parasite growth was in stark contrast to that of the other genetic factors under study. Although consistent evidence has been found for protective effects against severe malaria by G6PD deficiency, blood group O, the rs4951074 allele in <italic>ATP2B4</italic> and α<sup>+</sup>-thalassaemia in numerous previous studies (<xref ref-type="bibr" rid="bib18">Malaria Genomic Epidemiology Network, 2014</xref>; <xref ref-type="bibr" rid="bib31">Taylor et al., 2012</xref>), none of these polymorphisms had any significant impacts on any of the outcomes under investigation in this study. This is probably because, unlike Dantu, none of these conditions have a clearly established impact on merozoite red cell invasion, but instead influence the progress of malaria once the disease has become established. For example, recent studies have shown that α<sup>+</sup>-thalassaemia has no effect on either red blood cell invasion (<xref ref-type="bibr" rid="bib33">Williams et al., 2002</xref>) or the development of uncomplicated malaria (<xref ref-type="bibr" rid="bib31">Taylor et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Wambua et al., 2006</xref>), but protects instead against the development of severe and complicated disease through mechanisms that include the reduced expression of red cell surface antigens that result in cytoadhesion (<xref ref-type="bibr" rid="bib16">Krause et al., 2012</xref>; <xref ref-type="bibr" rid="bib23">Opi et al., 2014</xref>). Similarly, it had no apparent impact on infectivity in a previous, smaller, CHMI study using PfSPZ Challenge, conducted in Tanzania (<xref ref-type="bibr" rid="bib30">Shekalaghe et al., 2014</xref>). Because clinical guidelines mean that controlled human malaria challenge studies only ever reach relatively low-density parasitaemias, they may not adequately capture the impacts of genetic factors that influence the later, more severe stages of malaria disease. However, this study shows that they can be helpful in pointing towards the pathways leading to such outcomes for further study by other methods.</p><p>In conclusion, this study reveals the power of CHMI studies to deconvolute the malaria-protective effects of naturally occurring human genetic variants, establishes for the first time that the Dantu blood group provides strong protection against <italic>in vivo</italic> parasite growth, and emphasises the potential of Dantu-phenocopying interventions to limit <italic>P. falciparum</italic> growth <italic>in vivo</italic>.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>SLH and members of the CHMI-SIKA Study Team (YA, PFB, ERJ, TLR, and BKLS; see Author Information) are salaried, full-time employees of Sanaria, the manufacturer of Sanaria PfSPZ Challenge. The authors have no additional financial interests</p></fn><fn fn-type="COI-statement" id="conf4"><p>Melissa C Kapulu has received grants from UKRI MRC UK and Wellcome Trust and has received travel expenses for the HIC-VAC Annual Meeting, Greenwood Africa Prize and WHO working group meeting on challenge studies. The author has no other competing interests to declare</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Investigation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Formal analysis, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Supervision, Methodology, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Clinical trial registration: The study is registered on ClinicalTrials.gov (NCT02739763).</p></fn><fn fn-type="other"><p>The study was approved by both the KEMRI Scientific and Ethics Review Unit (protocol KEMRI/SERU/CGMR-C/029/3190) in Kenya, and the University of Oxford Tropical Research Ethics Committee (OxTREC; protocol 2-16) in the UK. The study was conducted based on good clinical practice (GCP) following the principles of the Declaration of Helsinki.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83874-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="repstand1"><label>Reporting standard 1.</label><caption><title>STREGA checklist.</title></caption><media xlink:href="elife-83874-repstand1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 2, 3, 4, and 5 and Tables 1, 2 and 3.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="1954">1954</year><article-title>Protection afforded by Sickle cell trait against Subtertian Malarial infection</article-title><source>British Medical Journal</source><volume>1</volume><fpage>290</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1136/bmj.1.4857.290</pub-id><pub-id pub-id-type="pmid">13115700</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Band</surname><given-names>G</given-names></name><name><surname>Rockett</surname><given-names>KA</given-names></name><name><surname>Spencer</surname><given-names>CCA</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><collab>Malaria Genomic Epidemiology Network</collab></person-group><year iso-8601-date="2015">2015</year><article-title>A novel locus of resistance to severe malaria in a region of ancient balancing selection</article-title><source>Nature</source><volume>526</volume><fpage>253</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1038/nature15390</pub-id><pub-id pub-id-type="pmid">26416757</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bejon</surname><given-names>P</given-names></name><name><surname>Andrews</surname><given-names>L</given-names></name><name><surname>Hunt-Cooke</surname><given-names>A</given-names></name><name><surname>Sanderson</surname><given-names>F</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name><name><surname>Hill</surname><given-names>AVS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Thick blood film examination for <italic>Plasmodium falciparum</italic> malaria has reduced sensitivity and Underestimates parasite density</article-title><source>Malaria Journal</source><volume>5</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-5-104</pub-id><pub-id pub-id-type="pmid">17092336</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Church</surname><given-names>LW</given-names></name><name><surname>Le</surname><given-names>TP</given-names></name><name><surname>Bryan</surname><given-names>JP</given-names></name><name><surname>Gordon</surname><given-names>DM</given-names></name><name><surname>Edelman</surname><given-names>R</given-names></name><name><surname>Fries</surname><given-names>L</given-names></name><name><surname>Davis</surname><given-names>JR</given-names></name><name><surname>Herrington</surname><given-names>DA</given-names></name><name><surname>Clyde</surname><given-names>DF</given-names></name><name><surname>Shmuklarsky</surname><given-names>MJ</given-names></name><name><surname>Schneider</surname><given-names>I</given-names></name><name><surname>McGovern</surname><given-names>TW</given-names></name><name><surname>Chulay</surname><given-names>JD</given-names></name><name><surname>Ballou</surname><given-names>WR</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Clinical manifestations of <italic>Plasmodium falciparum</italic> malaria experimentally induced by mosquito challenge</article-title><source>The Journal of Infectious Diseases</source><volume>175</volume><fpage>915</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1086/513990</pub-id><pub-id pub-id-type="pmid">9086149</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>GM</given-names></name><name><surname>Rockett</surname><given-names>K</given-names></name><name><surname>Kivinen</surname><given-names>K</given-names></name><name><surname>Hubbart</surname><given-names>C</given-names></name><name><surname>Jeffreys</surname><given-names>AE</given-names></name><name><surname>Rowlands</surname><given-names>K</given-names></name><name><surname>Jallow</surname><given-names>M</given-names></name><name><surname>Conway</surname><given-names>DJ</given-names></name><name><surname>Bojang</surname><given-names>KA</given-names></name><name><surname>Pinder</surname><given-names>M</given-names></name><name><surname>Usen</surname><given-names>S</given-names></name><name><surname>Sisay-Joof</surname><given-names>F</given-names></name><name><surname>Sirugo</surname><given-names>G</given-names></name><name><surname>Toure</surname><given-names>O</given-names></name><name><surname>Thera</surname><given-names>MA</given-names></name><name><surname>Konate</surname><given-names>S</given-names></name><name><surname>Sissoko</surname><given-names>S</given-names></name><name><surname>Niangaly</surname><given-names>A</given-names></name><name><surname>Poudiougou</surname><given-names>B</given-names></name><name><surname>Mangano</surname><given-names>VD</given-names></name><name><surname>Bougouma</surname><given-names>EC</given-names></name><name><surname>Sirima</surname><given-names>SB</given-names></name><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Amenga-Etego</surname><given-names>LN</given-names></name><name><surname>Ghansah</surname><given-names>A</given-names></name><name><surname>Koram</surname><given-names>KA</given-names></name><name><surname>Wilson</surname><given-names>MD</given-names></name><name><surname>Enimil</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Amodu</surname><given-names>OK</given-names></name><name><surname>Olaniyan</surname><given-names>S</given-names></name><name><surname>Apinjoh</surname><given-names>T</given-names></name><name><surname>Mugri</surname><given-names>R</given-names></name><name><surname>Ndi</surname><given-names>A</given-names></name><name><surname>Ndila</surname><given-names>CM</given-names></name><name><surname>Uyoga</surname><given-names>S</given-names></name><name><surname>Macharia</surname><given-names>A</given-names></name><name><surname>Peshu</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>TN</given-names></name><name><surname>Manjurano</surname><given-names>A</given-names></name><name><surname>Sepúlveda</surname><given-names>N</given-names></name><name><surname>Clark</surname><given-names>TG</given-names></name><name><surname>Riley</surname><given-names>E</given-names></name><name><surname>Drakeley</surname><given-names>C</given-names></name><name><surname>Reyburn</surname><given-names>H</given-names></name><name><surname>Nyirongo</surname><given-names>V</given-names></name><name><surname>Kachala</surname><given-names>D</given-names></name><name><surname>Molyneux</surname><given-names>M</given-names></name><name><surname>Dunstan</surname><given-names>SJ</given-names></name><name><surname>Phu</surname><given-names>NH</given-names></name><name><surname>Quyen</surname><given-names>NN</given-names></name><name><surname>Thai</surname><given-names>CQ</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Manning</surname><given-names>L</given-names></name><name><surname>Laman</surname><given-names>M</given-names></name><name><surname>Siba</surname><given-names>P</given-names></name><name><surname>Karunajeewa</surname><given-names>H</given-names></name><name><surname>Allen</surname><given-names>S</given-names></name><name><surname>Allen</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>TM</given-names></name><name><surname>Michon</surname><given-names>P</given-names></name><name><surname>Mueller</surname><given-names>I</given-names></name><name><surname>Molloy</surname><given-names>SF</given-names></name><name><surname>Campino</surname><given-names>S</given-names></name><name><surname>Kerasidou</surname><given-names>A</given-names></name><name><surname>Cornelius</surname><given-names>VJ</given-names></name><name><surname>Hart</surname><given-names>L</given-names></name><name><surname>Shah</surname><given-names>SS</given-names></name><name><surname>Band</surname><given-names>G</given-names></name><name><surname>Spencer</surname><given-names>CC</given-names></name><name><surname>Agbenyega</surname><given-names>T</given-names></name><name><surname>Achidi</surname><given-names>E</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Farrar</surname><given-names>J</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Taylor</surname><given-names>T</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><collab>MalariaGEN Consortium</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe Malarial anaemia</article-title><source>eLife</source><volume>6</volume><elocation-id>e15085</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.15085</pub-id><pub-id pub-id-type="pmid">28067620</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fry</surname><given-names>AE</given-names></name><name><surname>Griffiths</surname><given-names>MJ</given-names></name><name><surname>Auburn</surname><given-names>S</given-names></name><name><surname>Diakite</surname><given-names>M</given-names></name><name><surname>Forton</surname><given-names>JT</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name><name><surname>Jallow</surname><given-names>M</given-names></name><name><surname>Sisay-Joof</surname><given-names>F</given-names></name><name><surname>Pinder</surname><given-names>M</given-names></name><name><surname>Peshu</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>TN</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Molyneux</surname><given-names>ME</given-names></name><name><surname>Taylor</surname><given-names>TE</given-names></name><name><surname>Rockett</surname><given-names>KA</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Common variation in the ABO Glycosyltransferase is associated with susceptibility to severe <italic>Plasmodium falciparum</italic> malaria</article-title><source>Human Molecular Genetics</source><volume>17</volume><fpage>567</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddm331</pub-id><pub-id pub-id-type="pmid">18003641</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgson</surname><given-names>SH</given-names></name><name><surname>Juma</surname><given-names>E</given-names></name><name><surname>Salim</surname><given-names>A</given-names></name><name><surname>Magiri</surname><given-names>C</given-names></name><name><surname>Kimani</surname><given-names>D</given-names></name><name><surname>Njenga</surname><given-names>D</given-names></name><name><surname>Muia</surname><given-names>A</given-names></name><name><surname>Cole</surname><given-names>AO</given-names></name><name><surname>Ogwang</surname><given-names>C</given-names></name><name><surname>Awuondo</surname><given-names>K</given-names></name><name><surname>Lowe</surname><given-names>B</given-names></name><name><surname>Munene</surname><given-names>M</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>James</surname><given-names>ER</given-names></name><name><surname>Gunasekera</surname><given-names>A</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><name><surname>Njuguna</surname><given-names>P</given-names></name><name><surname>Rampling</surname><given-names>TW</given-names></name><name><surname>Richman</surname><given-names>A</given-names></name><name><surname>Abebe</surname><given-names>Y</given-names></name><name><surname>Kamuyu</surname><given-names>G</given-names></name><name><surname>Muthui</surname><given-names>M</given-names></name><name><surname>Elias</surname><given-names>SC</given-names></name><name><surname>Molyneux</surname><given-names>S</given-names></name><name><surname>Gerry</surname><given-names>S</given-names></name><name><surname>Macharia</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>TN</given-names></name><name><surname>Bull</surname><given-names>PC</given-names></name><name><surname>Hill</surname><given-names>AVS</given-names></name><name><surname>Osier</surname><given-names>FH</given-names></name><name><surname>Draper</surname><given-names>SJ</given-names></name><name><surname>Bejon</surname><given-names>P</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Ogutu</surname><given-names>B</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to <italic>Plasmodium falciparum</italic> using Sporozoites administered by Intramuscular injection</article-title><source>Frontiers in Microbiology</source><volume>5</volume><elocation-id>686</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2014.00686</pub-id><pub-id pub-id-type="pmid">25566206</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgson</surname><given-names>SH</given-names></name><name><surname>Douglas</surname><given-names>AD</given-names></name><name><surname>Edwards</surname><given-names>NJ</given-names></name><name><surname>Kimani</surname><given-names>D</given-names></name><name><surname>Elias</surname><given-names>SC</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Daza</surname><given-names>G</given-names></name><name><surname>Seilie</surname><given-names>AM</given-names></name><name><surname>Magiri</surname><given-names>C</given-names></name><name><surname>Muia</surname><given-names>A</given-names></name><name><surname>Juma</surname><given-names>EA</given-names></name><name><surname>Cole</surname><given-names>AO</given-names></name><name><surname>Rampling</surname><given-names>TW</given-names></name><name><surname>Anagnostou</surname><given-names>NA</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Draper</surname><given-names>SJ</given-names></name><name><surname>Bejon</surname><given-names>P</given-names></name><name><surname>Ogutu</surname><given-names>B</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Hill</surname><given-names>AVS</given-names></name><name><surname>Murphy</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood Inoculum size in controlled human malaria infection studies</article-title><source>Malaria Journal</source><volume>14</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-015-0541-6</pub-id><pub-id pub-id-type="pmid">25627033</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamau</surname><given-names>E</given-names></name><name><surname>Alemayehu</surname><given-names>S</given-names></name><name><surname>Feghali</surname><given-names>KC</given-names></name><name><surname>Komisar</surname><given-names>J</given-names></name><name><surname>Regules</surname><given-names>J</given-names></name><name><surname>Cowden</surname><given-names>J</given-names></name><name><surname>Ockenhouse</surname><given-names>CF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Measurement of Parasitological data by quantitative real-time PCR from controlled Human Malaria infection trials at the Walter Reed Army Institute of research</article-title><source>Malaria Journal</source><volume>13</volume><elocation-id>288</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2875-13-288</pub-id><pub-id pub-id-type="pmid">25066459</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapulu</surname><given-names>M</given-names></name><name><surname>Njuguna</surname><given-names>P</given-names></name><name><surname>Hamaluba</surname><given-names>MM</given-names></name><collab>CHMI-SIKA Study Team</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Controlled Human Malaria Infection in semi-immune Kenyan adults (CHMI-SIKA): a study protocol to investigate <italic>in vivo Plasmodium falciparum</italic> malaria parasite growth in the context of pre-existing immunity</article-title><source>Wellcome Open Research</source><volume>3</volume><elocation-id>155</elocation-id><pub-id pub-id-type="doi">10.12688/wellcomeopenres.14909.1</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapulu</surname><given-names>MC</given-names></name><name><surname>Njuguna</surname><given-names>P</given-names></name><name><surname>Hamaluba</surname><given-names>M</given-names></name><name><surname>Kimani</surname><given-names>D</given-names></name><name><surname>Ngoi</surname><given-names>JM</given-names></name><name><surname>Musembi</surname><given-names>J</given-names></name><name><surname>Ngoto</surname><given-names>O</given-names></name><name><surname>Otieno</surname><given-names>E</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><collab>Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA) Study Team</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.146443</pub-id><pub-id pub-id-type="pmid">34264864</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapulu</surname><given-names>MC</given-names></name><name><surname>Kimani</surname><given-names>D</given-names></name><name><surname>Njuguna</surname><given-names>P</given-names></name><name><surname>Hamaluba</surname><given-names>M</given-names></name><name><surname>Otieno</surname><given-names>E</given-names></name><name><surname>Kimathi</surname><given-names>R</given-names></name><name><surname>Tuju</surname><given-names>J</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><collab>CHMI-SIKA Study Team</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-Schizont antibody response</article-title><source>BMC Infectious Diseases</source><volume>22</volume><elocation-id>86</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-022-07044-8</pub-id><pub-id pub-id-type="pmid">35073864</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kariuki</surname><given-names>SN</given-names></name><name><surname>Kirou</surname><given-names>KA</given-names></name><name><surname>MacDermott</surname><given-names>EJ</given-names></name><name><surname>Barillas-Arias</surname><given-names>L</given-names></name><name><surname>Crow</surname><given-names>MK</given-names></name><name><surname>Niewold</surname><given-names>TB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cutting edge: Autoimmune disease risk variant of Stat4 confers increased sensitivity to IFN-alpha in lupus patients in vivo</article-title><source>Journal of Immunology</source><volume>182</volume><fpage>34</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.182.1.34</pub-id><pub-id pub-id-type="pmid">19109131</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kariuki</surname><given-names>SN</given-names></name><name><surname>Marin-Menendez</surname><given-names>A</given-names></name><name><surname>Introini</surname><given-names>V</given-names></name><name><surname>Ravenhill</surname><given-names>BJ</given-names></name><name><surname>Lin</surname><given-names>Y-C</given-names></name><name><surname>Macharia</surname><given-names>A</given-names></name><name><surname>Makale</surname><given-names>J</given-names></name><name><surname>Tendwa</surname><given-names>M</given-names></name><name><surname>Nyamu</surname><given-names>W</given-names></name><name><surname>Kotar</surname><given-names>J</given-names></name><name><surname>Carrasquilla</surname><given-names>M</given-names></name><name><surname>Rowe</surname><given-names>JA</given-names></name><name><surname>Rockett</surname><given-names>K</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name><name><surname>Weekes</surname><given-names>MP</given-names></name><name><surname>Cicuta</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>TN</given-names></name><name><surname>Rayner</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Red blood cell tension protects against severe malaria in the Dantu blood group</article-title><source>Nature</source><volume>585</volume><fpage>579</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2726-6</pub-id><pub-id pub-id-type="pmid">32939086</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimingi</surname><given-names>HW</given-names></name><name><surname>Kinyua</surname><given-names>AW</given-names></name><name><surname>Achieng</surname><given-names>NA</given-names></name><name><surname>Wambui</surname><given-names>KM</given-names></name><name><surname>Mwangi</surname><given-names>S</given-names></name><name><surname>Nguti</surname><given-names>R</given-names></name><name><surname>Kivisi</surname><given-names>CA</given-names></name><name><surname>Jensen</surname><given-names>ATR</given-names></name><name><surname>Bejon</surname><given-names>P</given-names></name><name><surname>Kapulu</surname><given-names>MC</given-names></name><name><surname>Abdi</surname><given-names>AI</given-names></name><name><surname>Kinyanjui</surname><given-names>SM</given-names></name><collab>CHMI-SIKA Study Team</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Breadth of antibodies to <italic>Plasmodium falciparum</italic> variant surface antigens is associated with immunity in a controlled human malaria infection study</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>894770</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.894770</pub-id><pub-id pub-id-type="pmid">35711446</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>MA</given-names></name><name><surname>Diakite</surname><given-names>SAS</given-names></name><name><surname>Lopera-Mesa</surname><given-names>TM</given-names></name><name><surname>Amaratunga</surname><given-names>C</given-names></name><name><surname>Arie</surname><given-names>T</given-names></name><name><surname>Traore</surname><given-names>K</given-names></name><name><surname>Doumbia</surname><given-names>S</given-names></name><name><surname>Konate</surname><given-names>D</given-names></name><name><surname>Keefer</surname><given-names>JR</given-names></name><name><surname>Diakite</surname><given-names>M</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>α-Thalassemia impairs the Cytoadherence of <italic>Plasmodium falciparum</italic>-infected Erythrocytes</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e37214</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0037214</pub-id><pub-id pub-id-type="pmid">22623996</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lell</surname><given-names>B</given-names></name><name><surname>Mordmüller</surname><given-names>B</given-names></name><name><surname>Dejon Agobe</surname><given-names>J-C</given-names></name><name><surname>Honkpehedji</surname><given-names>J</given-names></name><name><surname>Zinsou</surname><given-names>J</given-names></name><name><surname>Mengue</surname><given-names>JB</given-names></name><name><surname>Loembe</surname><given-names>MM</given-names></name><name><surname>Adegnika</surname><given-names>AA</given-names></name><name><surname>Held</surname><given-names>J</given-names></name><name><surname>Lalremruata</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Esen</surname><given-names>M</given-names></name><name><surname>Kc</surname><given-names>N</given-names></name><name><surname>Ruben</surname><given-names>AJ</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Lee Sim</surname><given-names>BK</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>James</surname><given-names>ER</given-names></name><name><surname>Richie</surname><given-names>TL</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Impact of Sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>98</volume><fpage>508</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.17-0343</pub-id><pub-id pub-id-type="pmid">29260650</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Malaria Genomic Epidemiology Network</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Reappraisal of known malaria resistance Loci in a large multicenter study</article-title><source>Nature Genetics</source><volume>46</volume><fpage>1197</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1038/ng.3107</pub-id><pub-id pub-id-type="pmid">25261933</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mordmüller</surname><given-names>B</given-names></name><name><surname>Supan</surname><given-names>C</given-names></name><name><surname>Sim</surname><given-names>KL</given-names></name><name><surname>Gómez-Pérez</surname><given-names>GP</given-names></name><name><surname>Ospina Salazar</surname><given-names>CL</given-names></name><name><surname>Held</surname><given-names>J</given-names></name><name><surname>Bolte</surname><given-names>S</given-names></name><name><surname>Esen</surname><given-names>M</given-names></name><name><surname>Tschan</surname><given-names>S</given-names></name><name><surname>Joanny</surname><given-names>F</given-names></name><name><surname>Lamsfus Calle</surname><given-names>C</given-names></name><name><surname>Löhr</surname><given-names>SJ</given-names></name><name><surname>Lalremruata</surname><given-names>A</given-names></name><name><surname>Gunasekera</surname><given-names>A</given-names></name><name><surname>James</surname><given-names>ER</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>Richman</surname><given-names>A</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Legarda</surname><given-names>A</given-names></name><name><surname>Muñoz</surname><given-names>J</given-names></name><name><surname>Antonijoan</surname><given-names>RM</given-names></name><name><surname>Ballester</surname><given-names>MR</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Alonso</surname><given-names>PL</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Direct venous inoculation of <italic>Plasmodium falciparum</italic> Sporozoites for controlled human malaria infection: A dose-finding trial in two centres</article-title><source>Malaria Journal</source><volume>14</volume><elocation-id>628</elocation-id><pub-id pub-id-type="doi">10.1186/s12936-015-0628-0</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>SC</given-names></name><name><surname>Prentice</surname><given-names>JL</given-names></name><name><surname>Williamson</surname><given-names>K</given-names></name><name><surname>Wallis</surname><given-names>CK</given-names></name><name><surname>Fang</surname><given-names>FC</given-names></name><name><surname>Fried</surname><given-names>M</given-names></name><name><surname>Pinzon</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Talley</surname><given-names>AK</given-names></name><name><surname>Kappe</surname><given-names>SHI</given-names></name><name><surname>Duffy</surname><given-names>PE</given-names></name><name><surname>Cookson</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Real-time quantitative reverse transcription PCR for monitoring of blood-stage <italic>Plasmodium falciparum</italic> infections in malaria human challenge trials</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>86</volume><fpage>383</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2012.10-0658</pub-id><pub-id pub-id-type="pmid">22403305</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musasia</surname><given-names>FK</given-names></name><name><surname>Nkumama</surname><given-names>IN</given-names></name><name><surname>Frank</surname><given-names>R</given-names></name><name><surname>Kipkemboi</surname><given-names>V</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Mwai</surname><given-names>K</given-names></name><name><surname>Odera</surname><given-names>DO</given-names></name><name><surname>Rosenkranz</surname><given-names>M</given-names></name><name><surname>Fürle</surname><given-names>K</given-names></name><name><surname>Kimani</surname><given-names>D</given-names></name><name><surname>Tuju</surname><given-names>J</given-names></name><name><surname>Njuguna</surname><given-names>P</given-names></name><name><surname>Hamaluba</surname><given-names>M</given-names></name><name><surname>Kapulu</surname><given-names>MC</given-names></name><name><surname>Wardemann</surname><given-names>H</given-names></name><name><surname>Osier</surname><given-names>FHA</given-names></name><collab>CHMI-SIKA Study Team</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Phagocytosis of <italic>Plasmodium falciparum</italic> ring-stage parasites predicts protection against malaria</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>4098</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-31640-6</pub-id><pub-id pub-id-type="pmid">35835738</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ndila</surname><given-names>CM</given-names></name><name><surname>Uyoga</surname><given-names>S</given-names></name><name><surname>Macharia</surname><given-names>AW</given-names></name><name><surname>Nyutu</surname><given-names>G</given-names></name><name><surname>Peshu</surname><given-names>N</given-names></name><name><surname>Ojal</surname><given-names>J</given-names></name><name><surname>Shebe</surname><given-names>M</given-names></name><name><surname>Awuondo</surname><given-names>KO</given-names></name><name><surname>Mturi</surname><given-names>N</given-names></name><name><surname>Tsofa</surname><given-names>B</given-names></name><name><surname>Sepúlveda</surname><given-names>N</given-names></name><name><surname>Clark</surname><given-names>TG</given-names></name><name><surname>Band</surname><given-names>G</given-names></name><name><surname>Clarke</surname><given-names>G</given-names></name><name><surname>Rowlands</surname><given-names>K</given-names></name><name><surname>Hubbart</surname><given-names>C</given-names></name><name><surname>Jeffreys</surname><given-names>A</given-names></name><name><surname>Kariuki</surname><given-names>S</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Mackinnon</surname><given-names>M</given-names></name><name><surname>Maitland</surname><given-names>K</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Rockett</surname><given-names>KA</given-names></name><name><surname>Williams</surname><given-names>TN</given-names></name><collab>MalariaGEN Consortium</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Human candidate Gene Polymorphisms and risk of severe malaria in children in Kilifi, Kenya: A case-control Association study</article-title><source>The Lancet. Haematology</source><volume>5</volume><fpage>e333</fpage><lpage>e345</lpage><pub-id pub-id-type="doi">10.1016/S2352-3026(18)30107-8</pub-id><pub-id pub-id-type="pmid">30033078</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opi</surname><given-names>DH</given-names></name><name><surname>Ochola</surname><given-names>LB</given-names></name><name><surname>Tendwa</surname><given-names>M</given-names></name><name><surname>Siddondo</surname><given-names>BR</given-names></name><name><surname>Ocholla</surname><given-names>H</given-names></name><name><surname>Fanjo</surname><given-names>H</given-names></name><name><surname>Ghumra</surname><given-names>A</given-names></name><name><surname>Ferguson</surname><given-names>DJP</given-names></name><name><surname>Rowe</surname><given-names>JA</given-names></name><name><surname>Williams</surname><given-names>TN</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mechanistic studies of the negative Epistatic malaria-protective interaction between Sickle cell trait and ⍺-thalassemia</article-title><source>EBioMedicine</source><volume>1</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2014.10.006</pub-id><pub-id pub-id-type="pmid">25893206</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2017">2017</year><data-title>R: A language and environment for statistical computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org">https://www.r-project.org</ext-link></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roestenberg</surname><given-names>M</given-names></name><name><surname>Bijker</surname><given-names>EM</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>James</surname><given-names>ER</given-names></name><name><surname>Bastiaens</surname><given-names>GJH</given-names></name><name><surname>Teirlinck</surname><given-names>AC</given-names></name><name><surname>Scholzen</surname><given-names>A</given-names></name><name><surname>Teelen</surname><given-names>K</given-names></name><name><surname>Arens</surname><given-names>T</given-names></name><name><surname>van der Ven</surname><given-names>AJAM</given-names></name><name><surname>Gunasekera</surname><given-names>A</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Velmurugan</surname><given-names>S</given-names></name><name><surname>Hermsen</surname><given-names>CC</given-names></name><name><surname>Sauerwein</surname><given-names>RW</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Controlled human malaria infections by intradermal injection of Cryopreserved <italic>Plasmodium falciparum</italic> Sporozoites</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>88</volume><fpage>5</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2012.12-0613</pub-id><pub-id pub-id-type="pmid">23149582</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>JA</given-names></name><name><surname>Handel</surname><given-names>IG</given-names></name><name><surname>Thera</surname><given-names>MA</given-names></name><name><surname>Deans</surname><given-names>A-M</given-names></name><name><surname>Lyke</surname><given-names>KE</given-names></name><name><surname>Koné</surname><given-names>A</given-names></name><name><surname>Diallo</surname><given-names>DA</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Kai</surname><given-names>O</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Moulds</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Blood group O protects against severe <italic>Plasmodium falciparum</italic> malaria through the mechanism of reduced Rosetting</article-title><source>PNAS</source><volume>104</volume><fpage>17471</fpage><lpage>17476</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705390104</pub-id><pub-id pub-id-type="pmid">17959777</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salkeld</surname><given-names>J</given-names></name><name><surname>Themistocleous</surname><given-names>Y</given-names></name><name><surname>Barrett</surname><given-names>JR</given-names></name><name><surname>Mitton</surname><given-names>CH</given-names></name><name><surname>Rawlinson</surname><given-names>TA</given-names></name><name><surname>Payne</surname><given-names>RO</given-names></name><name><surname>Hou</surname><given-names>MM</given-names></name><name><surname>Khozoee</surname><given-names>B</given-names></name><name><surname>Edwards</surname><given-names>NJ</given-names></name><name><surname>Nielsen</surname><given-names>CM</given-names></name><name><surname>Sandoval</surname><given-names>DM</given-names></name><name><surname>Bach</surname><given-names>FA</given-names></name><name><surname>Nahrendorf</surname><given-names>W</given-names></name><name><surname>Ramon</surname><given-names>RL</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Ramos-Lopez</surname><given-names>F</given-names></name><name><surname>Folegatti</surname><given-names>PM</given-names></name><name><surname>Quinkert</surname><given-names>D</given-names></name><name><surname>Ellis</surname><given-names>KJ</given-names></name><name><surname>Poulton</surname><given-names>ID</given-names></name><name><surname>Lawrie</surname><given-names>AM</given-names></name><name><surname>Cho</surname><given-names>J-S</given-names></name><name><surname>Nugent</surname><given-names>FL</given-names></name><name><surname>Spence</surname><given-names>PJ</given-names></name><name><surname>Silk</surname><given-names>SE</given-names></name><name><surname>Draper</surname><given-names>SJ</given-names></name><name><surname>Minassian</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Repeat controlled human malaria infection of healthy UK adults with blood-stage <italic>Plasmodium falciparum</italic>: Safety and parasite growth Dynamics</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>984323</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.984323</pub-id><pub-id pub-id-type="pmid">36072606</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seilie</surname><given-names>AM</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Hanron</surname><given-names>AE</given-names></name><name><surname>Billman</surname><given-names>ZP</given-names></name><name><surname>Stone</surname><given-names>BC</given-names></name><name><surname>Zhou</surname><given-names>K</given-names></name><name><surname>Olsen</surname><given-names>TM</given-names></name><name><surname>Daza</surname><given-names>G</given-names></name><name><surname>Ortega</surname><given-names>J</given-names></name><name><surname>Cruz</surname><given-names>KR</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><name><surname>Healy</surname><given-names>SA</given-names></name><name><surname>Neal</surname><given-names>J</given-names></name><name><surname>Wallis</surname><given-names>CK</given-names></name><name><surname>Shelton</surname><given-names>L</given-names></name><name><surname>Mankowski</surname><given-names>TV</given-names></name><name><surname>Wong-Madden</surname><given-names>S</given-names></name><name><surname>Mikolajczak</surname><given-names>SA</given-names></name><name><surname>Vaughan</surname><given-names>AM</given-names></name><name><surname>Kappe</surname><given-names>SHI</given-names></name><name><surname>Fishbaugher</surname><given-names>M</given-names></name><name><surname>Betz</surname><given-names>W</given-names></name><name><surname>Kennedy</surname><given-names>M</given-names></name><name><surname>Hume</surname><given-names>JCC</given-names></name><name><surname>Talley</surname><given-names>AK</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Chakravarty</surname><given-names>S</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><name><surname>Richie</surname><given-names>TL</given-names></name><name><surname>Wald</surname><given-names>A</given-names></name><name><surname>Plowe</surname><given-names>CV</given-names></name><name><surname>Lyke</surname><given-names>KE</given-names></name><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Fahle</surname><given-names>GA</given-names></name><name><surname>Cowan</surname><given-names>EP</given-names></name><name><surname>Duffy</surname><given-names>PE</given-names></name><name><surname>Kublin</surname><given-names>JG</given-names></name><name><surname>Murphy</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Beyond blood Smears: qualification of Plasmodium 18S rRNA as a biomarker for controlled human malaria infections</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>100</volume><fpage>1466</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.19-0094</pub-id><pub-id pub-id-type="pmid">31017084</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehy</surname><given-names>SH</given-names></name><name><surname>Duncan</surname><given-names>CJA</given-names></name><name><surname>Elias</surname><given-names>SC</given-names></name><name><surname>Choudhary</surname><given-names>P</given-names></name><name><surname>Biswas</surname><given-names>S</given-names></name><name><surname>Halstead</surname><given-names>FD</given-names></name><name><surname>Collins</surname><given-names>KA</given-names></name><name><surname>Edwards</surname><given-names>NJ</given-names></name><name><surname>Douglas</surname><given-names>AD</given-names></name><name><surname>Anagnostou</surname><given-names>NA</given-names></name><name><surname>Ewer</surname><given-names>KJ</given-names></name><name><surname>Havelock</surname><given-names>T</given-names></name><name><surname>Mahungu</surname><given-names>T</given-names></name><name><surname>Bliss</surname><given-names>CM</given-names></name><name><surname>Miura</surname><given-names>K</given-names></name><name><surname>Poulton</surname><given-names>ID</given-names></name><name><surname>Lillie</surname><given-names>PJ</given-names></name><name><surname>Antrobus</surname><given-names>RD</given-names></name><name><surname>Berrie</surname><given-names>E</given-names></name><name><surname>Moyle</surname><given-names>S</given-names></name><name><surname>Gantlett</surname><given-names>K</given-names></name><name><surname>Colloca</surname><given-names>S</given-names></name><name><surname>Cortese</surname><given-names>R</given-names></name><name><surname>Long</surname><given-names>CA</given-names></name><name><surname>Sinden</surname><given-names>RE</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name><name><surname>Lawrie</surname><given-names>AM</given-names></name><name><surname>Doherty</surname><given-names>T</given-names></name><name><surname>Faust</surname><given-names>SN</given-names></name><name><surname>Nicosia</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>AVS</given-names></name><name><surname>Draper</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Chad63-MVA-Vectored blood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans</article-title><source>Molecular Therapy</source><volume>20</volume><fpage>2355</fpage><lpage>2368</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.223</pub-id><pub-id pub-id-type="pmid">23089736</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shekalaghe</surname><given-names>S</given-names></name><name><surname>Rutaihwa</surname><given-names>M</given-names></name><name><surname>Billingsley</surname><given-names>PF</given-names></name><name><surname>Chemba</surname><given-names>M</given-names></name><name><surname>Daubenberger</surname><given-names>CA</given-names></name><name><surname>James</surname><given-names>ER</given-names></name><name><surname>Mpina</surname><given-names>M</given-names></name><name><surname>Ali Juma</surname><given-names>O</given-names></name><name><surname>Schindler</surname><given-names>T</given-names></name><name><surname>Huber</surname><given-names>E</given-names></name><name><surname>Gunasekera</surname><given-names>A</given-names></name><name><surname>Manoj</surname><given-names>A</given-names></name><name><surname>Simon</surname><given-names>B</given-names></name><name><surname>Saverino</surname><given-names>E</given-names></name><name><surname>Church</surname><given-names>LWP</given-names></name><name><surname>Hermsen</surname><given-names>CC</given-names></name><name><surname>Sauerwein</surname><given-names>RW</given-names></name><name><surname>Plowe</surname><given-names>C</given-names></name><name><surname>Venkatesan</surname><given-names>M</given-names></name><name><surname>Sasi</surname><given-names>P</given-names></name><name><surname>Lweno</surname><given-names>O</given-names></name><name><surname>Mutani</surname><given-names>P</given-names></name><name><surname>Hamad</surname><given-names>A</given-names></name><name><surname>Mohammed</surname><given-names>A</given-names></name><name><surname>Urassa</surname><given-names>A</given-names></name><name><surname>Mzee</surname><given-names>T</given-names></name><name><surname>Padilla</surname><given-names>D</given-names></name><name><surname>Ruben</surname><given-names>A</given-names></name><name><surname>Sim</surname><given-names>BKL</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Abdulla</surname><given-names>S</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved <italic>Plasmodium falciparum</italic> sporozoites</article-title><source>The American Journal of Tropical Medicine and Hygiene</source><volume>91</volume><fpage>471</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.14-0119</pub-id><pub-id pub-id-type="pmid">25070995</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SM</given-names></name><name><surname>Parobek</surname><given-names>CM</given-names></name><name><surname>Fairhurst</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Haemoglobinopathies and the clinical epidemiology of malaria: A systematic review and meta-analysis</article-title><source>The Lancet. Infectious Diseases</source><volume>12</volume><fpage>457</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(12)70055-5</pub-id><pub-id pub-id-type="pmid">22445352</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wambua</surname><given-names>S</given-names></name><name><surname>Mwangi</surname><given-names>TW</given-names></name><name><surname>Kortok</surname><given-names>M</given-names></name><name><surname>Uyoga</surname><given-names>SM</given-names></name><name><surname>Macharia</surname><given-names>AW</given-names></name><name><surname>Mwacharo</surname><given-names>JK</given-names></name><name><surname>Weatherall</surname><given-names>DJ</given-names></name><name><surname>Snow</surname><given-names>RW</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>TN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The effect of ⍺<sup>+</sup>-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya</article-title><source>PLOS Medicine</source><volume>3</volume><elocation-id>e158</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0030158</pub-id><pub-id pub-id-type="pmid">16605300</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>TN</given-names></name><name><surname>Weatherall</surname><given-names>DJ</given-names></name><name><surname>Newbold</surname><given-names>CI</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The membrane characteristics of <italic>Plasmodium falciparum</italic>-infected and -uninfected heterozygous ⍺⁰thalassaemic erythrocytes</article-title><source>British Journal of Haematology</source><volume>118</volume><fpage>663</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2141.2002.03610.x</pub-id><pub-id pub-id-type="pmid">12139762</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>T</given-names></name><name><surname>Wambua</surname><given-names>S</given-names></name><name><surname>Uyoga</surname><given-names>S</given-names></name><name><surname>Macharia</surname><given-names>A</given-names></name><name><surname>Mwacharo</surname><given-names>JK</given-names></name><name><surname>Newton</surname><given-names>CRJC</given-names></name><name><surname>Maitland</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Both heterozygous and homozygous ⍺⁺thalassemias protect against severe and fatal <italic>Plasmodium falciparum</italic> malaria on the coast of Kenya</article-title><source>Blood</source><volume>106</volume><fpage>368</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-01-0313</pub-id><pub-id pub-id-type="pmid">15769889</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>T.N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sickle cell disease in sub-Saharan Africa</article-title><source>Hematology/Oncology Clinics of North America</source><volume>30</volume><fpage>343</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2015.11.005</pub-id><pub-id pub-id-type="pmid">27040958</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>TN</given-names></name></person-group><year iso-8601-date="2017">2017</year><chapter-title>Host Genetics</chapter-title><person-group person-group-type="editor"><name><surname>Gaur</surname><given-names>G</given-names></name></person-group><source>Advances in Malaria Research</source><publisher-name>John Wiley &amp; Sons, Inc</publisher-name><fpage>465</fpage><lpage>494</lpage></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Members of the CHMI-SIKA Study Team</title><list list-type="simple"><list-item><p><bold>Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya:</bold> Abdirahman I Abdi, Philip Bejon, Zaydah de Laurent, Mainga Hamaluba, Domtila Kimani, Rinter Kimathi, Kevin Marsh, Sam Kinyanjui, Khadija Said Mohammed, Moses Mosobo, Janet Musembi, Jennifer Musyoki, Michelle Muthui, Jedidah Mwacharo, Kennedy Mwai, Joyce M Ngoi, Omar Ngoto, Patricia Njuguna, Irene Nkumama, Francis Ndungu, Dennis Odera, Donwilliams Omuoyo, Faith Osier, Edward Otieno, Jimmy Shangala, James Tuju, Juliana Wambua, Thomas N Williams</p></list-item><list-item><p><bold>Sanaria Inc, Rockville, MD, United States:</bold> Yonas Abebe, Peter F Billingsley, Stephen L Hoffman, Eric R James, Thomas L Richie, B Kim Lee Sim</p></list-item><list-item><p><bold>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University Oxford, Oxford, United Kingdom:</bold> Sam Kinyanjui, Kevin Marsh</p></list-item><list-item><p><bold>Department of Pathology, University of Cambridge, Cambridge, United Kingdom:</bold> Peter C Bull</p></list-item><list-item><p><bold>Pwani University, P. O. Box 195-80108, Kilifi, Kenya:</bold> Sam Kinyanjui, Cheryl Kivisi</p></list-item><list-item><p><bold>Epidemiology and Biostatistics Division, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa:</bold> Kennedy Mwai</p></list-item><list-item><p><bold>Centre for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany:</bold> Irene Nkumama, Dennis Odera, Faith Osier</p></list-item><list-item><p><bold>Center for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya:</bold> Bernhards Ogutu, Fredrick Olewe, John Ong’echa</p></list-item><list-item><p><bold>Center for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya:</bold> Bernhards Ogutu, Fredrick Olewe, John Ong’echa</p></list-item></list></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83874.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wesolowski</surname><given-names>Amy</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Johns Hopkins Bloomberg School of Public Health</institution><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.09.21.22280031" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.21.22280031"/></front-stub><body><p>The large genetic association studies conducted in East Africa have shown that the Dantu blood group provides substantial protection against severe malaria since it increases the surface tension of red blood cells making it harder for malaria parasites to invade. In this important work, the authors show that parasite growth is indeed restricted <italic>in vivo</italic> by testing this hypothesis in adult Kenyan volunteers infected with <italic>P. falciparium</italic> under careful monitoring. They were able to show convincingly that indeed, parasite growth was reduced amongst Dantu adults.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83874.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Wesolowski</surname><given-names>Amy</given-names></name><role>Reviewing Editor</role><aff><institution>Johns Hopkins Bloomberg School of Public Health</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Nahrendorf</surname><given-names>Wiebke</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>University of Edinburgh</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>White</surname><given-names>Nicholas J</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01znkr924</institution-id><institution>Mahidol University</institution></institution-wrap><country>Thailand</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.21.22280031">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.09.21.22280031v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;The Dantu blood group provides high level protection against uncomplicated malaria: evidence from a Controlled Human Malaria Infection study&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jos van der Meer as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Wiebke Nahrendorf (Reviewer #1); Nicholas J White (Reviewer #2). The reviewers have some suggestions to take into account when you resubmit.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Nice short paper showing that Dantu prevents parasite growth <italic>in vivo</italic>. I think it is important to be really clear that the mechanism of protection is that red cells are rigid so parasites cannot get in. This makes a lovely clear-cut story so I would recommend changing the title to something like &quot;The Dantu blood group prevents parasite growth <italic>in vivo</italic>.&quot; – simple (and exciting!).</p><p>At present the title and some of the wording around uncomplicated malaria is a little misleading: of course if there are no malaria parasites no malaria symptoms are experienced. &quot;Protection from uncomplicated malaria&quot; would to me imply that at identical parasite densities Dantu individuals experience less symptoms than non-Dantu – but this is of course not what the paper shows (and the study would not be powered to do so).</p><p>Below a few comments on how the data is presented – my recommendation is to incorporate the key bits of information from Tables in the Figures as it is hard to interpret dissociated information. Also more informative labels and legends (include details of statistical test and n) in the Figures would help them be more self-explanatory methods: more details for genotyping – primer sequences etc. what is the reference allele? more details &amp; references for R packages used for multivariate analysis. define fixed and random effects and all response variables.</p><p>Figure 2: More intuitive labelling: in text referred to as &quot;non Dantu&quot; &quot;Dantu heterozygotes&quot; and &quot;Dantu homozygotes&quot; – keep this in Figures for consistency (also for the other red cell polymorphisms). Why does the red group look different between the different polymorphisms? Does that mean e.g. G6PD contains Dantu heterozygotes/homozygotes? Should all polymorphisms be excluded? It was not clear to me what the control group is (&quot;homozygous reference&quot; is not mentioned in methods or elsewhere in text).</p><p>To help interpretation the number of participants in each graph should be included. My suggestion would be to incorporate the information of Table 1 into Figure 2: n could be indicated above each existing parasite growth curve graph, a small Figure (a bit like Figure 3) showing proportion of individuals that reached the parasitaemia threshold would fit next to it and could include p values. Bit more information in the legend would help the Figure to be more self-explanatory: &quot;Following inoculation of volunteers with Pf sporozoites parasitaemia was monitored by qPCR. Here split by red cell polymorphisms. The control (red) is xyz…&quot;.</p><p>I was also not quite clear on the red dots: do they indicate all treated participants – so when they either crossed 500 p/ul threshold or had any parasites + symptoms? In which case why are there some very high parasitaemias with no red dot? Or just febrile participants? Consider if this is the right place for this information given that this Figure is about parasite growth.</p><p>Table 1: My suggestion would be to incorporate the key info into corresponding Figure 2. The heading needs to make it to clear that this is related to parasite growth – the &quot;predefined threshold&quot; is 500 parasites/ul. I also think n is the number of participants being treated (not &quot;left untreated&quot; as stated). Please check the p values and indicate the statistical test/multiple testing correction used in legend – how can Dantu p-value Homozygous Reference vs Homozygous Derived be 1…? I imagine a Wilcoxon rank sum exact test (two-tailed) would be most appropriate.</p><p>Figure 3: Group labelling like Figure 2 (e.g. &quot;non Dantu&quot;). Heading a bit misleading – the outcome of treatment is not considered. If n in Figure 2 does not need to be repeated here above each bar. Instead incorporate p values from Table 2. In text explain what variables were adjusted for and provide a formula for your multivariate regression analysis: which dependent and independent variables did you use?</p><p>Table 2: incorporate information in Figure 3. Like in Table 1 n is the number of treated (not untreated) participants.</p><p>Table 3: Again I think &quot;treatment outcome&quot; in title is misleading. The multivariate model and which variables were adjusted for needs to be clearly stated in legend and Results section (currently in methods only but with not enough details).</p><p>Figure 4: descriptive title matching subheading in results might be better: &quot;Lower peak parasitaemia in Dantu-carrying participants&quot;. Axis labels and dots too small. Information from Table 4 could again be easily contained within this Figure.</p><p>Table 4: transfer key information to Figure 4. (or include a small Table in Figure 4)</p><p>Figure 5: Group labelling like Figure 2/3, axis labels too small. Condense the information provided within the table or at least highlight the key bits of information.</p><p>Figure 5 S1: Group labelling like Figure 2/3/5. I think this should go into Figure 5.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>This is a very nice study. The result is clear and the data on the other genetic human polymorphisms are also very interesting!</p><p>Here are a few points to consider:</p><p>1. qPCR is a lot less accurate than microscopy. Was the primary endpoint determined by microscopy also and if so how did the two methods compare?</p><p>2. Obvious questions, but I presume that other protective genetic polymorphisms were not linked, and the Dantu blood groups were not clustered in an ethnic group with more &quot;immunity&quot; i.e. from a focus of higher transmission? I think both were addressed -but wish to check.</p><p>3. Ideally growth rates would have been calculated but it looks as if the data are too noisy. Is that correct?</p><p>4. Have you counted merozoites per schizont and asexual cycle lengths in in-vitro cultures of <italic>P. falciparum</italic> infected Dantu blood group red cells to confirm there is no growth inhibition ?</p><p>5. How were blood samples screened for antimalarial drugs?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83874.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Nice short paper showing that Dantu prevents parasite growth in vivo. I think it is important to be really clear that the mechanism of protection is that red cells are rigid so parasites cannot get in. This makes a lovely clear-cut story so I would recommend changing the title to something like &quot;The Dantu blood group prevents parasite growth in vivo.&quot; – simple (and exciting!).</p></disp-quote><p>We thank the reviewer for this helpful comment. Following the reviewer’s suggestion, we have now changed the title to: The Dantu blood group prevents parasite growth <italic>in vivo</italic>: evidence from a Controlled Human Malaria Infection study.</p><disp-quote content-type="editor-comment"><p>At present the title and some of the wording around uncomplicated malaria is a little misleading: of course if there are no malaria parasites no malaria symptoms are experienced. &quot;Protection from uncomplicated malaria&quot; would to me imply that at identical parasite densities Dantu individuals experience less symptoms than non-Dantu – but this is of course not what the paper shows (and the study would not be powered to do so).</p></disp-quote><p>We agree that our study does not compare symptomatology across genotype groups. We have now removed wording about uncomplicated malaria from the title and the rest of the manuscript as suggested by this reviewer.</p><disp-quote content-type="editor-comment"><p>Below a few comments on how the data is presented – my recommendation is to incorporate the key bits of information from Tables in the Figures as it is hard to interpret dissociated information. Also more informative labels and legends (include details of statistical test and n) in the Figures would help them be more self-explanatory methods: more details for genotyping – primer sequences etc. what is the reference allele? more details &amp; references for R packages used for multivariate analysis. define fixed and random effects and all response variables.</p></disp-quote><p>Thank you for this helpful comment. We have now added details of the primer/probe sequences used to genotype the Dantu marker SNP, as well as the reference allele, to the Methods section of the revised paper on page 6. The multivariate analysis was performed with the glm function in the stats package (version 3.6.2), with the response variables being the Dantu marker SNP, other malaria-protective SNPs, anti-schizont antibody levels and area of residence. We have now included details of this and other packages within R that we used in our analyses to the statistical analysis section on page 7.</p><disp-quote content-type="editor-comment"><p>Figure 2: More intuitive labelling: in text referred to as &quot;non Dantu&quot; &quot;Dantu heterozygotes&quot; and &quot;Dantu homozygotes&quot; – keep this in Figures for consistency (also for the other red cell polymorphisms).</p></disp-quote><p>Thank you for this. We previously used “homozygous reference”, “heterozygous” and “homozygous derived” as a generalised labelling for the genotype categories in each of the different red cell polymorphisms. In the light of this comment, we have now clarified these genotype categories in the legend to Figure 2, while also amending the description for the Dantu group within this Figure for ease of reference. We hope this addresses this point to the reviewer’s satisfaction.</p><disp-quote content-type="editor-comment"><p>Why does the red group look different between the different polymorphisms?</p></disp-quote><p>In this Figure, the group coloured in red are the homozygous reference groups for each gene under investigation. In all cases, this group contains the largest number of individuals, but the precise number of individuals will differ depending on the minor allele frequency of each specific gene – this explains why the red group looks different in each case.</p><disp-quote content-type="editor-comment"><p>Does that mean e.g. G6PD contains Dantu heterozygotes/homozygotes? Should all polymorphisms be excluded?</p></disp-quote><p>As noted above, in this Figure the groups coloured in red are the homozygous reference individuals for each gene under investigation. Each of these genotypic groups will also include (by random chance) individuals of different genotypes for the other variants of interest. As the genotyping was conducted at the end of the study, and the study included only a relatively small number of individuals overall, it was not possible to limit each group to those who were reference homozygotes for all the other variants of interest. Instead, we used multivariable analyses to check that any differences seen on univariate analysis were not explained by the presence of other variants or confounders; these multivariate analyses clearly showed that the effect of Dantu was not due to such confounders. We hope this addresses the reviewer’s query. We have amended the text to address this point on page 11 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>It was not clear to me what the control group is (&quot;homozygous reference&quot; is not mentioned in methods or elsewhere in text).</p></disp-quote><p>No “control” group was included in this specific analysis. The overall p-values presented in the table were derived using Fisher’s exact tests, that were used to test for differences in the proportions of individuals that reached the pre-defined treatment threshold of 500 parasites/ml across ALL genotype groups – i.e. a global rather than a paired approach. We have added an explanation about the statistical methods involved both in the footnote to Figure 2 and in the Methods section on page 7.</p><disp-quote content-type="editor-comment"><p>To help interpretation the number of participants in each graph should be included. My suggestion would be to incorporate the information of Table 1 into Figure 2: n could be indicated above each existing parasite growth curve graph, a small Figure (a bit like Figure 3) showing proportion of individuals that reached the parasitaemia threshold would fit next to it and could include p values. Bit more information in the legend would help the Figure to be more self-explanatory: &quot;Following inoculation of volunteers with Pf sporozoites parasitaemia was monitored by qPCR. Here split by red cell polymorphisms. The control (red) is xyz…&quot;.</p></disp-quote><p>Thank you for this suggestion. We have now modified Figure 2 as suggested to include more information both on each graph and in the legend.</p><disp-quote content-type="editor-comment"><p>I was also not quite clear on the red dots: do they indicate all treated participants – so when they either crossed 500 p/ul threshold or had any parasites + symptoms? In which case why are there some very high parasitaemias with no red dot? Or just febrile participants? Consider if this is the right place for this information given that this Figure is about parasite growth.</p></disp-quote><p>The red dots indicate just the febrile participants (not all of them exhibited febrile symptoms even at the very high parasitaemias). We have now added an explanation about this point to the Figure legend.</p><disp-quote content-type="editor-comment"><p>Table 1: My suggestion would be to incorporate the key info into corresponding Figure 2. The heading needs to make it to clear that this is related to parasite growth – the &quot;predefined threshold&quot; is 500 parasites/ul. I also think n is the number of participants being treated (not &quot;left untreated&quot; as stated). Please check the p values and indicate the statistical test/multiple testing correction used in legend – how can Dantu p-value Homozygous Reference vs Homozygous Derived be 1…? I imagine a Wilcoxon rank sum exact test (two-tailed) would be most appropriate.</p></disp-quote><p>Due to the low sample sizes in the different genotype categories, we used the Fisher’s exact test to compare the proportions of individuals that reached the pre-defined treatment threshold of 500 parasites/ml (see the numbers in the table below). Both global comparisons across genotype groups and pairwise comparisons between genotype groups were done using the Fisher’s exact test. We did not correct for multiple testing in the pairwise analyses because we did separate comparisons of the proportion of individuals that reached the treatment threshold of 500 parasites/ml in the heterozygous and homozygous derived genotypes to the homozygous reference genotype. We have updated the footnote to <xref ref-type="table" rid="sa2table1">Author response table 1</xref> to explain the statistical methods that were used in better detail.</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><table frame="hsides" rules="groups"><thead><tr><th>Dantu genotype group</th><th>Below 500 parasites/ul</th><th>Above 500 parasites/ul</th><th>Sum</th></tr></thead><tbody><tr><td align="left" valign="top">Non-Dantu (AA)</td><td align="left" valign="top">86</td><td align="left" valign="top">25</td><td align="left" valign="top">111</td></tr><tr><td align="left" valign="top">Dantu Heterozygote (AG)</td><td align="left" valign="top">27</td><td align="left" valign="top">0</td><td align="left" valign="top">27</td></tr><tr><td align="left" valign="top">Dantu Homozygote</td><td align="left" valign="top">3</td><td align="left" valign="top">0</td><td align="left" valign="top">3</td></tr></tbody></table></table-wrap><p>Contingency table for maximum PCR values categorised as below 500 parasites/ul and above 500 parasites/ul</p><disp-quote content-type="editor-comment"><p>Figure 3: Group labelling like Figure 2 (e.g. &quot;non Dantu&quot;). Heading a bit misleading – the outcome of treatment is not considered. If n in Figure 2 does not need to be repeated here above each bar. Instead incorporate p values from Table 2. In text explain what variables were adjusted for and provide a formula for your multivariate regression analysis: which dependent and independent variables did you use?</p></disp-quote><p>Thank you for this. We have now added more information in this Figure about the numbers of individuals in each genotype group that required treatment, as well as the p-values from the Fisher’s exact tests comparing the differences in proportions of individuals that required treatment across genotype groups. The results from the multivariate regression are listed in Table 3. We have added further details to the Methods section on pages 7 and 8 about the Fisher’s exact test and multivariate regression models used.</p><disp-quote content-type="editor-comment"><p>Table 2: incorporate information in Figure 3. Like in Table 1 n is the number of treated (not untreated) participants.</p></disp-quote><p>Our apologies for this. We have corrected the information on the number of treated participants in the legend and included the p-values comparing the proportions of individuals requiring treatment across genotypes in Figure 3.</p><disp-quote content-type="editor-comment"><p>Table 3: Again I think &quot;treatment outcome&quot; in title is misleading. The multivariate model and which variables were adjusted for needs to be clearly stated in legend and Results section (currently in methods only but with not enough details).</p></disp-quote><p>We agree with this point. We have now edited the title and legend to make it clearer that it is the impact of each gene variant on treatment requirement that we are analysing. We have also added further details to the legend and the Results section on page 9 regarding the multivariate models used.</p><disp-quote content-type="editor-comment"><p>Figure 4: descriptive title matching subheading in results might be better: &quot;Lower peak parasitaemia in Dantu-carrying participants&quot;. Axis labels and dots too small. Information from Table 4 could again be easily contained within this Figure.</p></disp-quote><p>We thank the reviewer for this helpful suggestion. We have now edited the subheading of Figure 4 and incorporated the information from Table 4 into this figure accordingly.</p><disp-quote content-type="editor-comment"><p>Table 4: transfer key information to Figure 4. (or include a small Table in Figure 4)</p></disp-quote><p>Thank you. We have now included a small Table in Figure 4.</p><disp-quote content-type="editor-comment"><p>Figure 5: Group labelling like Figure 2/3, axis labels too small. Condense the information provided within the table or at least highlight the key bits of information.</p><p>Figure 5 S1: Group labelling like Figure 2/3/5. I think this should go into Figure 5.</p></disp-quote><p>We have now edited Figure 5 into a multi-part figure including Figure 5 S1.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>This is a very nice study. The result is clear and the data on the other genetic human polymorphisms are also very interesting!</p><p>Here are a few points to consider:</p><p>1. qPCR is a lot less accurate than microscopy. Was the primary endpoint determined by microscopy also and if so how did the two methods compare?</p></disp-quote><p>Because of the clinical guidelines around CHMI studies, participants need to be treated very early, meaning parasites only ever reach a relatively low density. In a previous publication (Bejon et al. Malaria J 2006, new Ref. # 16), parasite density measurements by qPCR and microscopy were compared using serially diluted parasite cultures of known parasitaemia. This study clearly showed that qPCR gives more accurate readings of parasite numbers at low densities, while thick blood films are less reproducible. As a consequence, we used qPCR as the primary endpoint measurement of parasitaemia in our current study, and it is also routinely used as the primary endpoint in CHMI studies conducted by other groups around the world (Refs. # 17 – 23). Thick blood smears were also performed but this was as an additional clinical precaution, with participants being treated if they became blood film positive at any density. We have added more information in the Methods section on page 5 to clarify this point, and added the references discussed here.</p><disp-quote content-type="editor-comment"><p>2. Obvious questions, but I presume that other protective genetic polymorphisms were not linked, and the Dantu blood groups were not clustered in an ethnic group with more &quot;immunity&quot; i.e. from a focus of higher transmission? I think both were addressed -but wish to check.</p></disp-quote><p>While all 3 Dantu homozygotes came from the same location (Kilifi South), as noted in the response to Reviewer 1, we compared anti-schizont antibody levels of all individuals to assess “immunity” and used the readings as a factor in our multivariate analysis. We found no differences in anti-schizont antibody levels, a correlate of pre-existing immunity to malaria, between the genetic groups. We have now included these data in Figure 3 —figure supplement 1.</p><disp-quote content-type="editor-comment"><p>3. Ideally growth rates would have been calculated but it looks as if the data are too noisy. Is that correct?</p></disp-quote><p>This is correct. Growth rates were calculated in a previous study (Kapulu et al. BMC Infect Dis, 2022; Ref. # 21), and they were indeed found to be too noisy to allow for meaningful further analysis. This is because, to a variable extent, all of the participants had been previously exposed to malaria infections and their growth rate measurement data varied very significantly as a result, compared to what you would expect among malaria-naïve individuals such as those used in CHMI malaria vaccine trials. Of course, it would be next to impossible to perform CHMI to explore malaria-protective genotypes, which are enriched in African populations, with completely malaria-naïve individuals. We have not changed the manuscript in this regard but would be happy to add a comment in the discussion if helpful.</p><disp-quote content-type="editor-comment"><p>4. Have you counted merozoites per schizont and asexual cycle lengths in in-vitro cultures of <italic>P. falciparum</italic> infected Dantu blood group red cells to confirm there is no growth inhibition ?</p></disp-quote><p>This is a good suggestion but, unfortunately, because we used qPCR, rather than microscopy, as our primary method for tracking parasitaemia, we are not able to count merozoites per schizont and asexual cycle lengths in infected Dantu variant red cells in this study. This would require further <italic>in vitro</italic> experiments rather than this study’s <italic>in vivo</italic> experimental design, where for clinical reasons, treatment intervention guidelines mean that parasitaemia levels are never sufficiently high to generate such data.</p><disp-quote content-type="editor-comment"><p>5. How were blood samples screened for antimalarial drugs?</p></disp-quote><p>Antimalarial drugs were measured retrospectively in all volunteers at two time points, the day before the challenge and eight days after challenge. Their plasma samples were tested in two independent laboratories: Strathmore University in Nairobi, Kenya, which measured sulfadoxine, pyrimethamine, and chloroquine levels; and Mahidol Oxford Tropical Medicine Research Unit in Bangkok, Thailand, which measured artemether and dihydroartemisinin concentrations. All drug concentrations were measured by liquid chromatography-tandem mass spectrometry. These methods were detailed in a previous publication (Kapulu et al. JCI Insight 2021; Ref. # 21). We have now referenced this paper more clearly in the revised manuscript and have also summarised this in the Methods section on page 6.</p><p>In addition to these specific changes we have made in response to the reviewer comments, on reviewing our analyses we note that, unfortunately, we found a minor error in the script underlying the multivariable analysis included in Table 3. We have now corrected that error and re-run the analysis which made no material difference to our initial conclusions. The revised p-values are now shown in the updated table. Finally, we have also made a number of small changes to deal with typographical errors and issues of clarity.</p></body></sub-article></article>